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SUMMARY 
 
 
Pharmaceutical Evaluation of Phela Capsules used as Traditional 
Medicine   
 
 
Phela is a traditional herbal medicine comprising four plants, which together are 
claimed to have immune boosting properties. The Indigenous Knowledge Systems 
(IKS) program of the South African Medical Research Council (SAMRC) focuses on 
investigating such claims. The purpose of this study was to establish (from literature) 
a series of criteria and specifications that are appropriate to establish the 
pharmaceutical quality of plant-containing capsules such as Phela and to assess the 
pharmaceutical quality of Phela, in capsule form, and its suitability for use in clinical 
trials. Thus, the organoleptic features and physical and chemical properties of the 
individual plant powders and the content uniformity, release characteristics and shelf 
life of the capsules were determined. 
First, the current literature on the quality control of herbal provided by the British 
Pharmacopeia (BP), European Medicine Agency (EMEA) and World Health 
Organisation (WHO) were reviewed and a list of quality control parameters, methods 
and specifications that could be used to assess the pharmaceutical quality of the Phela 
plant materials and capsules were drawn up.  Then, the freshly prepared powders of 
the four individual plant materials and the final mixture were assessed for their 
organoleptic features, ash value, flowability, moisture content, extractable matter and 
microbial contamination using standard pharmacopoeia methods. Gelatine hard 
capsules of the 4 combined plant materials were manufactured at the SAMRC’s IKS 
Lead Programme under GMP conditions. The in vitro dissolution of the capsules was 
determined using the USP basket method and release of the plant drug monitored by 
 III 
UV spectroscopy.  The capsule was subjected to accelerated stability testing for 
estimation of a shelf life.  An HPLC assay and fingerprint method was employed for 
this purpose.  
 
Overall the Phela capsule contents had a uniformly light brown colour, bitter taste and 
characteristic medicinal odour which could be masked by a capsule dosage form. 
Particle size and shape determinations showed that the four plant powders and the 
mixture were not gradable. The four crude plant powders (RM, PT, CG, S) and the 
Phela mixture had similar flow properties (i.e. angles of repose of 39.233±3.85°, 
39.41±1.85°, 35.91±3.24°, 38.16±4.59° and 37.92±1.28°, respectively) and acceptable 
moisture content levels (i.e. 9.28±0.31 %, 8.58±0.43 %, 9.31±0.06 %, 10.29±0.53 % 
and 9.77±0.08 % respectively) which was unchanged in the final mixture. The water 
soluble or extractable matter was very high for plant PT (77.99±5.82 %) and low for 
plant S (32.79±2.87 %). The heavy metal, pesticides and microbial levels were within 
acceptable WHO standards.  
 
The manufacture of the capsules did not constitute any problems and the 
manufactured capsules had a high mass content uniformity (0.42 ±0.01 mg) and 
complied with BP standards in that the  masses of not more than two of the individual 
capsules deviated from the average weight (mass) by more than 7.5 %. The capsules 
released 50.39 % of its active ingredients within 45 minutes. HPLC fingerprinting and 
pattern recognition analysis indicated that there were 5 compounds in the Phela 
capsules that decreased by 22 % and 70 % of their original levels after 12 and 24 
weeks of storage, respectively, under elevated temperature 40 
0
C and 70 % relative 
 IV 
humidity conditions. The 5 compounds had an average shelf-life (i.e. t90) of 6.1 weeks 
under these accelerated test conditions. 
 
 
In conclusion, the results obtained firstly indicated that the BP, EMEA and WHO 
were in fairly good agreement on the criteria and specifications that can be used to 
assesses the pharmaceutical quality of a traditional plant medicine such as Phela. 
Secondly, the Phela plant powders were found to have acceptable pharmaceutical 
properties that did not complicate or adversely affected the capsule manufacture. 
Thirdly, the Phela capsules produced were generally of acceptable pharmacopoeial 
standard. Fourthly, HPLC fingerprinting and pattern recognition analysis proved 
useful to examine the chemical stability of selected marker compounds of Phela and 
indicated that the capsules had no practical shelf life under elevated temperature and 
humid conditions. Overall, the Phela capsules should thus be suitable for use in a 
short time clinical trial, but for use in a long period trial the long term stability of the 
Phela capsules under ambient conditions must still be confirmed.  
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Chapter 1 
Introduction 
 
Herbs used in traditional medicine are nowadays frequently manufactured as 
conventional pharmaceutical dosage forms i.e. tablets, capsules and solutions, but 
these are generally not properly evaluated for their pharmaceutical properties. The 
Indigenous Knowledge Systems unit (IKS) of the South African Medical Research 
Council (SAMRC) works in partnership with Traditional Healers (TH’s) to 
manufacture pharmaceutical dosage forms of traditional medicines for the TH’s.  
Little is however known about the pharmaceutical quality of these traditional 
preparations, the characteristics of the plant raw material and how it will react with 
other excipients or adulterants, etc.   
 
In a traditional setting, liquid dosage forms of herbal medicines are generally 
preferred and the general preparation of such plant-containing material does not seem 
to follow generally accepted pharmaceutical manufacturing procedures, nor are the 
final preparations likely to meet conventional pharmaceutical or suitable quality 
standards. In fact, the afore-mentioned traditional liquid dosage forms may suffer 
from several disadvantages. For example, they may be prone to physical, 
phytochemical and microbiological instability (Wichtl, 1994) the preparations are 
often bitter in taste and unpalatable resulting in poor patient compliance, the unit 
doses may produce storage difficulties, etc. In most cases, adequate standards for 
traditional herbal dosage forms have not been optimally formulated and the 
pharmaceutical quality of the traditional herbal medicines not adequately evaluated by 
standard scientific methods. The formulation, manufacture and evaluation of capsules 
of plant material should be equally or even more complicated. 
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The formulation, manufacture and evaluation of pharmaceutical herbal dosage forms 
are complex procedures and mainly so because of the nature of the herbal ingredients 
contained in such preparations. “Firstly, the herbal ingredients are complex mixtures 
of different secondary metabolites that can vary considerably depending on 
environmental and genetic factors. Secondly, the constituents responsible for the 
plants’ claimed therapeutic effects are frequently unknown or only partly explained 
which precludes the level of pharmaceutical control that can routinely be achieved 
with synthetic drugs and conventional pharmaceutical preparations. These complex 
positions of quality aspects of herbal drugs are further complicated by the use of 
combinations of herbal ingredients as is common in traditional practice” (Mukherjee, 
2002). 
 
The increasing demand for herbal remedies (which represent a substantial proportion 
of the global drug market) both in the developing and developed countries, has 
inevitably led to the requirement that the quality and purity of the herbal raw materials 
and finished products also must be stringently maintained. For instance in Germany, 
most herbal drugs, even mixtures of herbal drugs, are registered as conventional 
drugs. This means that they meet the same stringent criteria of quality, efficacy, and 
safety as synthetic drugs (Wagner, 1999). In Germany, both medical practitioners and 
patients alike have continuously harnessed the use of traditional medicines. Moreover, 
that country’s pharmaceutical industry specialises in and relies on herbal drugs and 
has developed, and supported projects aimed to optimise the quality of herbal drugs 
through standardisation. 
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The World Health Organisation (WHO), the Food and Drug Administration (FDA) 
and European Medicines Agency (EMEA) have set basic criteria for the evaluation of 
the quality of herbal medicines for scientific organisations and manufacturers. All 
procedures should be in accordance with Good Manufacturing Practice. (Annex I, 
WHO, 2000). In addition a quality measure for phytopharmaceuticals in the form of a 
“monograph” or “master file,” is needed to define the individual quality criteria and 
specifications for every phytopharmaceutical (Bauer, 1998). 
 
As indicated earlier on, the SAMRC’s IKS unit works in partnership with TH’s on 
herbal medicines based on the history of use. ―This is done by providing indigenous 
communities with the support resources and tools to understand external influences on 
their environment and adapt to changes, ensuring the preservation and continuation of 
their practices‖ (SAMRC’s IKS website). Thus SAMRC’s IKS unit manufactures 
capsules of herbal medicines for TH’s (SAMRC’s IKS). Phela is one such capsule 
product that is presently being produced by SAMRC’s IKS unit. This unit has opted 
to make capsules of the Phela herbal medicine because the use of hard gelatine 
capsule dosage form could perhaps overcome some of the problems associated with 
the liquid traditional dosage forms. The capsule is a small cylindrical soluble 
container enclosing a dose of medicine. The capsule shell is an excellent barrier to air, 
and it also has some advantages such as being easy to swallow and tasteless, and may 
allow rapid release, flexibility of formulation and a short manufacturing process 
(Haiqui Ma, 2006). 
 
However the vegetable gelatine capsule herbal product designated Phela that IKS unit 
is presently making has not yet been optimally evaluated for its pharmaceutical 
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properties and quality. For instance, the actual plant material used has not been 
evaluated for optimal formulation into a solid dosage form preparation. Ground, dried 
plant material seldom have the appropriate pharmaceutical properties e.g. uniform 
particle size, adequate flow characteristics, mass uniformity, taste, etc, that allows 
easy incorporation of such plant material into solid dosage forms of good quality. In 
addition, the finished capsules need to be evaluated for mass and content uniformity, 
appearance, dissolution and stability.  
Consequently, the objectives of this study were to: 
a) Establish (from literature) a series of criteria and specifications that are 
appropriate to establish the pharmaceutical quality of plant-containing 
capsules such as Phela, 
b) Assess the pharmaceutical quality of the finished Phela capsules,  
c) Assess the pharmaceutical quality of the ―formulated‖ Phela raw material, and 
d)         Provide a certificate of analysis for the finished capsules.  
The realisation of the afore-mentioned objectives would allow the determination 
whether the Phela capsules made by SAMRC’s IKS unit is of acceptable 
pharmaceutical quality and suitable for use in a clinical trial. 
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Chapter 2 
 
Introduction (Background) 
 
In this chapter an overview is presented on the traditional medicine Phela, 
pharmaceutical issues concerning herbal medicine and the pharmaceutical evaluation 
of herbal dosage forms.  
2.1. What is Phela? 
 
Phela is a crude botanical product constituting four plants collected in different 
regions of South Africa and combined in a specific ratio to make herbal traditional 
medicine. However, due to legal requirements (Intellectual Property Rights) 
individual plant names cannot be given in full in this dissertation. For the purposes of 
this study, the four constituent of Phela will thus be referred to as plants PT, CG, RM 
and S.  
 
Plant PT is a perennial plant of the family Agavaceae which is endemic to Mexico and 
grows in forests or grasslands. The scales of these bulbs are reputed as antispasmodic 
and Plant PT is particularly known as a traditional aid for the treatment of malaria. 
Plant CG is a shrub which belongs to the family Verbenaceae, and grows in tropical 
Africa and Asia. Growing in dense bushveld, rocky hillsides and forest verges, the 
leaves are used in traditional medicine to help treat coughs, intestinal worms and 
convulsions. Plant RM is also a member of Verbenaceae family and is native to 
tropical East Africa. Ethiopians traditionally used it as treatment for pneumonia, 
malaria, gonorrhoea and urine infections (Desissa, 2000). 
.  
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Plant S belongs to the family Fabaceae, and varies from a semi-woody annual herb in 
warm temperate areas to a woody annual shrub or sometimes a short-lived perennial 
shrub found in frost-free areas. This plant is indigenous to Brazil and used 
traditionally to treat fevers, menstrual problems, tuberculosis, anaemia, liver 
complaints, and as a general tonic. The leaves are also used for gonorrhoea, fever, 
urinary tract disorders, oedema, and menstrual problems. In Panama, the tea of the 
leaf is used for stomach colic, while the crushed leaves are often used as filling for a 
poultice due to its anti-inflammatory properties.  
 
The natural Phela product is under investigation for its potential health protection or 
disease inhibiting properties by the Indigenous Knowledge Systems (IKS) Unit of the 
South African Medical Research Council (SAMRC). Very little is known about the 
safety, efficacy, toxicity, formulation and pharmaceutical quality of Phela. The 
absence of quality control requirements for potency and purity of herbal preparations 
is a major concern due to the variation in chemical content and composition between 
samples and some may not even contain the assumed active contents (Patnala, 2008). 
Irrespective of its use, it is a requirement to assess for safety, efficacy and 
pharmaceutical quality if used by the people.  
2.1.1. Traditional claims of Phela 
 
 
Phela has been used for decades in patients with wasting conditions and for increasing 
energy. The medicine has been reported to have benefits for immune compromised 
individuals due to its immune stimulant effects and for the condition traditionally 
called “muyaka” (personal communication with traditional healer on MRC file). The 
 7 
disease “muyaka” is characterised by the following symptoms in bed-ridden patients:  
severe chest problems with coughing, coated or pimply tongue, high temperature and 
fevers that resulted in shivers and headaches, severe weight and appetite loss, 
vomiting and diarrhoea, stiffness, oral ulcers and slow painful death. These 
observational and anecdotal findings have been reported by medical doctors, through 
patient testimonies and by traditional practitioners, who independently, also reported 
beneficial effects gained by patients using the traditional medicine (on SAMRC’ IKS 
files).  
 
The South African Medical Research Council (SAMRC), through the Indigenous 
Knowledge Systems (IKS) program is actively involved in traditional medicine 
research. Their purpose is developing new forms of therapy from traditional herbal 
medication, which are efficacious and safe to use. The claims made by traditional 
healers about the therapeutic effect of herbs for certain diseases make it necessary to 
explore the potential of these medicines. Phela is one such herbal product that is being 
evaluated by the IKS unit but if the claims for efficacy, safety and quality of this 
traditional medicines is to be scientifically assessed an adequate and consistent dosage 
form is required.  
2.1.2. Traditional dosage forms of Phela 
 
The traditional method of preparation for Phela is by infusion and decoction. Such 
preparations are administered orally (from SAMRC’ IKS files). These liquid 
preparations are the most popular forms used. In general, infusions are typically made 
of delicate herbs, leaves and fresh tender plants and prepared by boiling water which 
is poured over the herbs or a combination of herbs (Ma, 2006). The ratio of herb to 
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water can vary depending on the remedy, the plant, and whether cut herb or powdered 
herb is being used. Generally, using 1 teaspoon (3 grams) of powdered herb or 2 
teaspoons (6 grams) of more bulky cut herb in a 6 to 8 ounce (170 ml to 230 ml) cup 
of water is sufficient (Taylor, 2004).  
 
Despite being relatively easy, preparing decoctions of herbs is not the most efficient 
method of extracting active ingredients. Quite a substantial amount of ingredients 
would have to be extracted to obtain the highest possible amount of extracted 
material. During the decocting process, the plant material is boiled for as long as it 
takes to soften the hard woody material for active ingredients be released (Taylor, 
2004). Most of these problems may however be remedied by using an appropriate 
solid or alternative dosage forms. 
2.1.3. Need for an alternative dosage form for Phela 
 
Traditional dosage forms have some disadvantages. They have poor stability during 
storage, they are not immediately available for use and are susceptible to microbial 
contamination. The preparation of traditional medicine is time consuming and the 
product usually deteriorates when heated, has an inconsistent mass and has poor 
content uniformity. While, by subtle variation in method of preparation and 
formulation, these medicines can easily be made to suit the palatability of the patients 
and to elicit the required potency of the drug, such variation in preparation may 
however lead to inconsistencies and non-reproducibility in the quality and efficacy of 
such individualized medicines. To solve some of the afore-mentioned disadvantages 
several types of dosage forms for herbal preparations are under development at the 
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MRC i.e. the traditional herbal liquid preparation, standardised dried plant powder 
extracts and capsules or tablets containing dried plant powder.   
 
The use of extracts allows one to achieve authenticity, assay and chemical constituent 
analysis (Torey, et al, 2010). Extracts are made by immersing large quantities of plant 
material into water and thereafter removing the water by freeze drying. Authenticity 
relates to proving that the material is true i.e. it corresponds with the right identity 
(Yadav, et al, 2008). Purity pertains to evaluating that there are no adulterants present 
in the plant material (Yadav, et al, 2008). The assay part of standardisation is the 
assessment of the chemical and biological profiling (Yadav, et al, 2008). Safety is 
assessed through clinical use. Extracts from plant material can be qualitatively and 
quantitatively assessed for authenticity.  
The capsule or tablet dosage form contains the dry plant powder or plant extract 
powder that replaces 2-3 teaspoonfuls of herbs as the herbal dosage form. Apart from 
being smaller, capsules and tablet are also easier to carry and easy to swallow, better 
to produce, pack and store. However, all capsules and tablets must meet certain 
pharmaceutical standards, which are mostly based on physical appearance of the 
dosage form and the consistency of its chemical components. Whatever dosage a form 
is used to replace the traditional form should be of suitable quality is crucial.  
 
.   
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2.1.4. Specific aspects of the quality of Phela 
 
Quality assurance of botanicals and herbal preparations is the prerequisite of clinical 
trials (Sahoo, et al, 2010). Therefore before any dosage form of Phela produced can 
be used in a clinical trial, the pharmaceutical quality of such a dosage form must be 
assured. This includes assuring the quality of each component plant materials of Phela 
as well as the final dosage form (e.g. capsule), 
 
The basic prerequisites for quality control of each component include authentication 
of the herbal ingredient, inter/intra species variation in plants, environmental factors, 
plant parts used and the contamination of herbal ingredients. The authentication and 
cultivation is done according to Good Laboratory Practice (GLP) and Good 
Agricultural Practice (GAP) guidelines respectively. These guidelines ensure that the 
plant raw material fulfils highest quality standards.  
 
To ensure quality, the individual tests for identity such as morphological identification 
(macroscopic and microscopic identification), chemical analysis such as Thin Layer 
Chromatography (TLC), High Performance Liquid Chromatography (HPLC), 
capillary electrophoresis, HPLC coupled with Mass Spectra (LC/MS), protein analysis 
and the use of molecular markers are conducted (Sahoo, et al, 2010). In addition, all 
the plant drugs are to be tested for microbiological contaminations, the content of 
heavy metals, pesticides and aflotoxins or other mycotoxins. These measurements 
ensure that only plant drugs of a high quality are used, which is a precondition for the 
production of standardized herbal preparations is complying with the set quality 
requirements (Kroll, et al, 2006). The quality of the herbal starting material shows 
more and more fluctuations due to varied geographical locations where the indigenous 
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plants grow, the different vernacular names they have and the great deal of 
substitution found in commercial markets (Yadav,  et al,  2008). 
 
The quality of the final dosage form (e.g. capsule or tablet) of Phela must also be 
assured, but for this one expects to be able to use the standardized methods and 
specifications generally applied for the pharmaceutical assurance of such dosage 
forms (see later).    
2.2. Pharmaceutical issues concerning herbal medicines 
 
 
The issues that are specific to quality control of herbal medicines are: (1) herbal drugs 
are mixtures of several constituents and are more difficult to characterize, (2) the 
active principle(s) are not always known and may be a mixture of compounds from 
different classes of flavonoids, (3) selective analytical methods may not yet exist, (4) 
reference compounds may not be commercially available, (5) harvesting, drying, and 
storage conditions have an influence on the raw material, (6) processing of extracts 
influences the chemical constituents e.g. solvent polarity and mode of extraction can 
alter the concentrations of constituents and instability of constituents may influence 
composition of the extract (Bauer, 1998). 
 
Natural products have traditionally been the basis of most of the drugs in use, but 
these days we are witnessing an increase in herbal remedy usage throughout the 
western world, raising doubts about the safety of these rapidly emerging products. 
The dilemma facing most regulatory authorities is that consumers consider these 
products as either traditional medicines or natural food supplements (Rousseaux, et al, 
2003). They do not necessarily concern themselves with product regulation. All 
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countries have laws concerning food, drugs and cosmetics, but the legislation seldom 
clearly define the regulation of alternative remedies. Complementary/alternative 
medicine (CAM) is an umbrella term for a collection of different approaches to 
diagnosis and treatment ((Barnes, 2003). In most countries alternative remedies are 
regulated as foods, provided that no medicinal claim has been made against the label 
(Rousseaux, et al, 2003). 
 
 
The pharmaceutical quality requirement of many complementary medicines is a cause 
for concern (Barnes, 2003). Manufacturers of licensed complementary medicines, are 
required to demonstrate to the Medicines Control Agency (MCA) that their products 
meet standards for pharmaceutical quality (as well as safety and efficacy), i.e. that 
they manufacture in accordance with the principles of GMP (Barnes, 2003). However, 
manufacturers of unlicensed products are not required to do this and therefore there is 
no guarantee that such products meet standards for pharmaceutical quality (Barnes, 
2003).  
 
Existing herbal ingredients of complementary medicine encompass complex mixtures 
of secondary metabolites that can vary considerably depending on environmental and 
genetic factors which will make it a difficult to determine the expiry date or shelf-life. 
Even when the chemical composition of a plant extract is known, the 
pharmacologically active moiety (ies) may not be known (Boullata, et al, 2000). The 
evaluation of herbal dosage forms should be established on the source of the raw 
material, quality, purity and the herbal dosage form.  
 
 
 
 13 
2.3. Evaluation of the quality of herbal dosage forms  
 
 
The important basic factors in the evaluation of herbal dosage forms includes the 
criteria and specification for the manufactured and finished products, the quality 
control of the starting (raw) plant material of herbal products and quality control 
guidelines for herbal dosage forms in assessing the safety, efficacy of a herbal 
medicine and dissolution are discussed. 
2.3.1. The criteria and specification for the quality control of herbal dosage 
forms  
 
Acceptance criteria and specification are the foremost important features of the 
quality control for herbal dosage forms. Acceptance criterion is one of the key 
features of the quality control for manufactured and finished herbal products. An 
acceptance criterion establishes specifications, i.e. qualitative and quantitative 
characteristics, with test procedures and acceptance limits for the medicinal product 
during its intended shelf life (EMEA, 2006a). For herbal medicinal products, the 
quality control criteria used is mainly found in different pharmacopoeia like British 
pharmacopoeia (1999), European Pharmacopoeia (1997), etc. For example, the 
procedures and specifications concerning the microscopic characteristics, chemical 
identification tests, total ash and hydrochloric acid insoluble ash levels, particle size, 
inorganic impurities and heavy metals limit tests, microbial contamination limit tests, 
mycotoxins presence tests and pesticide residue tests can all (clearly) be obtained 
from the pharmacopoeias and used to evaluate the quality of the crude herbal drugs.  
 
Specification is defined as a list of tests, references to analytical and biological 
procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or 
 14 
other criteria for the tests described. It establishes the set of criteria to which an (1) 
herbal substance (2) herbal preparation and (3) herbal medicinal product should 
conform to be considered acceptable for its intended use (EMEA, 2001). The setting 
of specifications for 1, 2 and 3 is part of an overall quality control strategy which 
includes control of raw materials and add-ons, in-process testing, process 
evaluation/validation, stability testing and testing for consistency of batches. When 
combined in total, these elements provide assurance that the appropriate quality of the 
product will be maintained (EMEA, 2006). Familiarity with the scientific and 
technical literature regarding the specifications of chemical substances for 
pharmaceutical use is of primary importance, particularly for those working in Quality 
Assurance (QA) /Quality Control (QC), production and formulation development.The 
differences in pharmacopoeial specifications among regions usually exist. A 
harmonized global specification is possible if the procedures and acceptance criteria 
defined are acceptable to regulatory authorities in all regions. In case there is no 
available pharmacopoeial monograph, raw material manufacturers must establish 
approved specification and all other scientific data according to the technical 
guidelines, general monographs and good manufacturing practice (GMP) 
requirements. To ensure whether the plant material meets the required quality criteria 
or specifications it is essential that the raw plant materials be subjected to quality 
control tests. 
2.3.2. The quality of the starting (raw) plant material of herbal products 
 
The quality requirements for raw material extends from the time the crude drug is 
collected and distributed, through the stages of processing and manufacture into an 
herbal medicinal product, and on to the final product reaching the consumer. Raw 
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material can be defined as starting material or any intermediate which will be used for 
further processing (WHO, 2010). The source and quality of raw materials, good 
agricultural practices (GAP) and manufacturing processes are certainly essential steps 
for the quality control of herbal medicines and play a pivotal role in sustaining the 
quality and stability of herbal preparations (EMEA, 2002; WHO, 1998; WHO, 2000). 
Before finished pharmaceutical dosage forms are produced, the identity, purity and 
quality of raw materials (as per specifications for impurities and other related 
substances present) must be established by means of suitable testing methods (Sapna, 
et al, 2007). The raw material must be tested for microbial contamination, pesticide 
and fumigation agents, toxic metals, and other likely contaminants and adulterants. 
 
The control of botanicals must be carefully planned in order to obtain plant materials 
which are both suitable as well as safe for use. This includes the botanical source, 
plant parts used and its state (i.e. whole, reduced, powdered, fresh, or dry). An 
assessment of the quality of the starting material and excipients are required. The 
information on the site of collection, time of harvesting, stage of growth, drying and 
storage conditions should be documented (WHO, 2004). In the case of herbal drugs 
with constituents with known activity, assays of their content using validated methods 
are required. This content must be stated as a range in order to ensure reproducibility 
(EMEA, 2001). 
2.3.3. Quality control guidelines for the assessment of herbal dosage forms  
 
 
The quality control guidelines of raw material of herbal products and herbal dosage 
forms are done according to description set by the BP or USP monographs. The BP 
and USP provide useful guidelines on quality control assessment for herbal medicine 
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and their preparations are standardized, regulated and quality is controlled according 
to guidelines described in the official compendiums. These guidelines for the 
assessment of herbal medicines are intended to facilitate the work of regulatory 
authorities, scientific bodies and industry in the development, assessment and 
registration of herbal products (WHO, 1991). The herbal product monographs listed in 
the BP and USP are useful checkpoints for quality evaluation on herbal medicines and 
herbal medicine preparations such as qualitative and quantitative assessment of the 
active substance, description of the method of preparation of the herbal medicinal, 
stability and dissolution test. 
2.3.4. Dissolution 
 
Dissolution testing is a method for evaluating physiological availability that depends 
upon having the drug in a dissolved state (Saccone, et al, 2004). Dissolution test 
measures the portion (%) of the Active Pharmaceutical Ingredient (API) that has been 
released from tablets/capsules and has dissolved in the dissolution medium during 
controlled testing conditions within a defined period. It is one of the most important 
and useful in-vitro tests for assuring product quality and batch to batch consistency 
(Kanfer, 2009). In vitro dissolution often aids in guiding the section of prototype 
formulation and often helps to determine optimum amounts of ingredients needed to 
achieve requisite drug release profiles. Dissolution also provides information on the 
impact of changes in composition, process or site of manufacturing which can help in 
identify potential problems of in vivo release and bioavailability absorption following 
administration.  
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Dissolution of drugs from solid dosage forms is a key parameter in assessing the 
product quality and uniformity at the formulation stage and throughout the shelf-life 
of the product (He, et al, 2004). The significance of a dissolution test is the fact that a 
drug should be in solution form to ensure that it is absorbed and available to systemic 
circulation (He, et al, 2004). In order for a drug to have its desired effect after oral 
administration, it must be soluble and diffuse through the gut wall into the body. The 
first step in that process is the disintegration of the dosage form followed by 
dissolution of the active ingredient. Dissolution of a pure substance follows the Noyes 
Whitney Equation: 
 
 dc/dt = kS (Cs- Ct)      equation   2.4 
 
Where dc/dt is the rate of dissolution, k is the dissolution rate constant, S is the 
surface area of the dissolving solid, Cs is the saturation concentration of the drug in 
the diffusion layer and Ct is the concentration of the drug in dissolution media (or the 
bulk).  
 
There is a scientific framework for classifying drug substances based on their aqueous 
solubility and intestinal permeability. The Biopharmaceutics Classification System 
(BCS) was originally developed for chemically defined synthetic drug substances, but 
it may also help with Herbal Medicinal Products (HMPs) (Blume, et al, 2000). When 
combined with the dissolution of the drug product, the BCS takes into account three 
major factors that govern the rate and extent of drug absorption from immediate-
release solid oral dosage forms: dissolution, solubility, and intestinal permeability.  
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According to the BCS, drug substances are classified as follows:  
Class 1: High Solubility = High Permeability; Class 2: Low Solubility = High 
Permeability; Class 3: High Solubility = Low Permeability; and Class 4: Low 
Solubility = Low Permeability.  In addition, solid oral dosage forms are categorized as 
having rapid or slow dissolutions. Within this framework, when certain criteria are 
met, the BCS can be used as a drug development tool to help funders justify requests 
for biowaivers.  
 
Unlike orthodox medicines, specific guidelines for dissolution testing of 
complementary/alternative have not been developed (Nair, et al, 2008). Compendia 
methods for botanicals products, such as the BP or USP, apparatus I (basket), II 
(paddle) and III (reciprocating cylinder) and disintegration test may be used to 
evaluate the in vitro release characteristics of the dosage form. Generally, dissolution 
testing of solid oral dosage forms is carried out by the basket (USP apparatus 1) 
method under mild agitation (100 rpm with the basket) in aqueous buffer in the pH 
range 1.2 to 6.8. The data obtained could be presented as percentage of dissolved 
material as function of time and pH. 
2.4. Characterisation of the quality of the starting plant materials of Phela 
 
Herbal drug preparations are diverse in character and vary from simple, comminute 
plant material to extracts. Based on recent scientific data, a comprehensive 
specification must be developed for every herbal drug preparation. 
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2.4.1. Characteristics of relevance in the evaluation of Phela raw materials 
 
The test parameters which are discussed below should be recommended for the 
quality control of herbal drug preparation relevant to Phela: 
2.4.1.1. Organoleptic features   
 
Organoleptic refers to any sensory properties of a product involving taste, colour, 
odour and feel or texture. Organoleptic testing involves inspection through visual 
examination, feeling and smelling of products. 
 
Colour is a vital means of identification for many pharmaceuticals, capsules and is 
usually important for consumer acceptance (Odeku, 2005). The colour of the product 
must be uniform within a single tablet, from tablet to tablet and from lot to lot 
(Sekharan, et al, 2010). Non-uniformity of colouring not only lack visual appeal but 
also could be associated by the consumer with non-uniformity of content and poor 
product quality (Sekharan, et al, 2010). Non-uniformity of colour is referred to as 
mottling. The eye cannot differentiate small differences in colour nor can it precisely 
define colour and efforts have been made to quantitate colour evaluations.  
 
Odour may also be important for consumer acceptance of tablets and can provide an 
indication of the quality of tablets as the presence of an odour in a batch of tablets 
could indicate a stability problem, such as the characteristic odour of acetic acid in 
degrading aspirin tablets. However, the presence of an odour may be characteristic of 
the drug (e.g. vitamins), added ingredients (e.g. flavouring agent) or the dosage form 
(e.g. film-coated tablets).  
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Taste is also important for consumer acceptance of certain tablets (e.g. chewable 
tablets) and many companies utilize taste panels to judge the preference of different 
flavours and flavour levels in the development of a product. Taste preference is 
however subjective and the control of taste in the production of chewable tablets is 
usually based on the presence or absence of a specified taste.  
2.4.1.2. Microscopic and macroscopic properties of powders 
 
 
Sieving is one of the fundamental methods for the classification of powders, and it is 
the method of choice for determining the size distribution of coarse powders (Brittain, 
2002). Microscopic examination of the raw drug substance provides an indication of 
particle size and particle size range of the drug substance, as well as its structure 
(Allen, 2008). During some processing procedures, the solid drug powders must flow 
freely and not become entangled or agglomerated. Spherical and oval-shaped powders 
flow more easily than needle-shaped powders and may facilitate processing.  
 
Particle size, and particle size distribution affects certain physical and chemical 
properties of drug substances, such as drug dissolution rate, bioavailability, content 
uniformity, taste, texture, color, and stability (Allen, 2008). They both play significant 
roles in flowability and other properties, such as bulk density, angle of repose, and 
compressibility of bulk solids (Ganesan, et al, 2008). Flow characteristics and 
sedimentation rates (suspensions) are also important factors related to particle size. It 
is essential to establish, as early as possible in the formulation process, how the 
particle size of the drug substance may affect formulation and product efficacy (Allen, 
2008).   
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Even a small change in particle size can cause significant alterations in the resulting 
flowability. Particle size influences the production of formulated medicine as solid 
dosage forms.  Reduction in particle size often tends to decrease the flowability of a 
given granular material due to the increased surface area per unit mass (Fitzpatrick, 
2004a and Fitzpatrick, 2004b). 
 
Quality control of herbal drugs has traditionally been based on appearance. Today, 
microscopic evaluation is crucial in the initial identification of herbs, as well as in 
identifying small fragments of crude or powdered herbs, and for detecting foreign 
matter and adulterants. A primary visual evaluation, which seldom needs more than a 
simple magnifying lens, can be used to ensure that the plant is of the required species, 
and that the right part of the plant is being used. Sometimes microscopic analysis is 
needed to determine the correct species or verify that the correct part of the species is 
present.   
2.4.1.3. Water content 
 
It is important to perform a verification test when the herbal drug preparation 
(especially extracts) are known to be (water-loving) hygroscopic. One characteristic 
of hygroscopic powders is that they continuously change their physicochemical 
properties when exposed to relative humidity and temperature conditions that either 
favour the absorption or loss of moisture (Teunou, 1999). The moisture acquired due 
to the hygroscopicity of the powder may lead to the degradation of the powder when 
enzymes like glycosidase are activated. Water impurities generally include minerals, 
viruses, bacteria and other organic material. 
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2.4.1.4. Aqueous solubility 
 
The solubility of a compound depends upon the physical and chemical properties of 
the solute and the solvent. Solubility is sensitive to changes in temperature according 
to Le Chatelier's Principle. Solubility will increase with decreasing size of solute 
particle (or droplet) because of the additional surface energy. This effect is generally 
small unless particles become very small, typically smaller than 1 μm. The effect of 
the particle size on solubility constant can be quantified as follows: 
                         equation 2.1 
where 
*
 KA is the solubility constant for the solute particles with the molar 
surface area A, is the solubility constant for substance with molar surface 
area tending to zero (i.e., when the particles are large), γ is the surface tension of the 
solute particle in the solvent, Am is the molar surface area of the solute (in m
2
/mol), R 
is the gas constant and T is the absolute temperature.
 
  
 
 The extraction of any crude drug with a particular solvent yields a solution containing 
different phyto-constituents. The use of a single solvent sample can be the means of 
providing preliminary information on the quality of a particular drug sample. This 
method determines the amount of active constituents extracted with solvents from a 
given amount of medicinal plant material. It is employed for materials for which there 
is still no suitable chemical or biological assay exists (WHO, 1998). 
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2.4.1.5. Microbial contamination  
 
Microbial contamination is associated with algae, bacteria and fungi (Kneifel, et al, 
2002). Inevitably, this microbiological background depends on several environmental 
factors and exerts an important impact on the overall quality of herbal products and 
preparations (Kneifel, et al, 2002). Risk assessment of the microbial load of medicinal 
plants has therefore become an important subject in the establishment of modern 
Hazard Analysis and Critical Control Point schemes. Microbial contamination of 
medicinal plant parts could be the result of inappropriate harvesting and cleaning of 
raw plant material, unhygienic processing of plants and incorrect transport 
mechanisms. 
 
Plants intended for use in botanical dietary supplements should be cultivated using 
Good Agricultural Practice (GAP). This approach provides quality assurance by 
helping to prevent microbial, heavy metal, herbicide, and pesticide contamination and 
by excluding weeds and insects. If wild plant specimens are collected or plant 
material is purchased from suppliers without GAP assurance, they should be assayed 
for levels of pesticides, herbicides, heavy metals, and microbes (van Breemen, et al, 
2007). 
2.4.1.6. Level of heavy metal and pesticides 
 
A common misperception is that natural substances cannot be present in toxic 
concentrations in a variety of herbal preparations and dietary supplements (Ernest, 
1998). The study entitled “Heavy metal hazards of Nigerian Herbal Remedies” 
revealed that high levels of iron, nickel, cadmium, copper, lead, selenium, and zinc 
would cause adverse health effects when regularly taken as recommended (Obi, et al, 
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2006). Failure to establish the true cause of exposure means that the patient continues 
to take the metal-containing medication. Thus, the screening of traditional remedies 
for efficacy and safety has been recommended to protect the general public. Heavy 
metals are known contaminants or adulterants of many traditional remedies (Obi, et 
al, 2006). The WHO is not yet in a position to recommend limits for contaminants 
since these are too diverse and there remains a lack of consensus on the matter (WHO, 
2005). The risks are particularly high when the therapeutic preparation contains 
numerous plants, like Phela capsules. 
 
The need for inclusion of tests and acceptance criteria for inorganic impurities should 
be studied during the development and based on knowledge of relevant plant species, 
their cultivation and manufacturing processes. Acceptance criteria will ultimately 
depend on safety considerations. Where justified, procedures and acceptance criteria 
for sulphated ash or residue, on ignition, should follow pharmacopoeial precedents; 
other inorganic impurities may be determined by other appropriate procedures, e.g., 
atomic absorption spectroscopy. 
 
The medicinal plants material can be contaminated with heavy metals and pesticides 
which can be attributed to many causes including environmental pollution and traces 
of pesticides (Street, 2008). As these components even in trace amounts can be 
dangerous, they have to be removed from the medicinal products. Limit test for these 
materials have been prescribed by the WHO (WHO, 2007). They have also 
established the maximum residue limit (MRL) for biocides in the medicinal plant 
cultivation. The MRL is calculated after safety test in human beings, which indicate 
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toxicologically accepted levels according to the reliable assay available. The MRL is 
calculated using the following formula. 
 
   MRL =                   ADI x W                   equation 2.2 
  MDI x [100 x (safety factor)] 
 
Where MRL = Maximum Residue Limits (mg/kg) 
            ADI = Acceptable Daily Intake (mg compounds/ kg body weight) 
            W = Body weight (kg) 
             MDI = Mean daily intake of drug 
 
When the herbal crude drug is used to prepare extracts, tinctures or other 
phytopharmaceutical formulations in which the manipulation may influence the 
pesticides concentration of the final product, the MRL is calculated as: 
 
 
   MRL =                    ADI x W x E             equation 2.3  
  MDI x [100 x (safety factor)] 
 
Where E = the extraction coefficient of the pesticide, which depend on the     
method of preparation and needs to be experimentally determined. 
  
 
The WHO (2007) on guidelines for assessing quality of herbal medicines with 
reference to contaminants and residues were used to assess the acceptability level of 
heavy metals in herbal medicines. 
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2.5. Analytical techniques for quality control of herbal capsules 
 
Analytical methods such as photometric analysis, Thin Layer Chromatography (TLC), 
High Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC) 
can be used to establish the constant composition of Phela herbal preparations. In 
cases where active ingredients are unknown or have become too complex, the quality 
of plant extracts can be assessed by means of a chromatographic fingerprint.  
 
The approach for the mainstream pharmaceutical industry has been to identify novel 
single-entity drugs for any given disease or condition. Once a candidate drug is 
established, a harmonized, standard quality–control measure is applied. The quality of 
single-entity pharmaceuticals is based on the correct chemical identity, purity and 
consistency.  
 
The chemical identity of pure starting material is established by physicochemical 
characteristics based on melting point; ultraviolet-visible (UV-Vis); infrared (IR); 
mass spectral (MS); nuclear magnetic resonance (NMR); spectra; and X-ray data. 
Analytical techniques such as high-performance thin-layer chromatography (HPTLC); 
high-performance liquid chromatography (HPLC); gas-chromatography (GC); and 
capillary electrophoresis (CE) reveal the purity or impurity profiles and establish 
consistency (Govindaraghavan, 2008). 
 
Purity is closely linked with the safe use of drugs as it deals with factors such ash 
values, contaminants (e.g. foreign matter in the form of other herbs), and heavy 
metals. However, due to the application of improved analytical methods, modern 
purity evaluation also includes microbial contamination, aflotoxins, radio activity and 
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pesticide residue testing. In this study HPLC assay can then be used to measure the 
flavonoid content of the capsule dosage form. 
 
2.6. Flavonoids used as chemical markers for quality control.    
 
 
Phela is rich in chemicals (such as flavonoids) that can be used effectively as markers 
in the analytical procedures for the content uniformity and dissolution tests of Phela 
capsules. These flavonoids may contribute to the biological activity of and could be 
appropriate phytochemicals to monitor quality control studies of Phela herbal dosage 
forms. These chemical compounds should be used as markers and the quantification 
by HPLC analysis is a viable method to help evaluate the herbal capsules. HPLC and 
mass spectrometry are some of the modern techniques used as tools for identification 
and quantitative analysis of flavonoids (Harborne, 2000). 
 
Attempts to adopt a similar concept (as explained above) for quality control purposes 
of herbal medicine raise immediate difficulties. Firstly, herbal medicines are complex 
mixture of diverse constituents, therefore purity or impurity profiles cannot be easily 
established as can be done with single-entity drugs. Secondly, the quality of herbal 
medicine has to be evaluated with an understanding of the complexity of the raw 
materials which it contains. Strict quality control guidelines are not available to help 
assess complex interactions, such as synergism and antagonism among constituent 
mixtures (Govindaraghavan, 2008). 
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Chapter 3 
 
Plan of work 
 
In this chapter, the specific objectives, hypothesis and study approach for this study are 
described. 
3.1. Objectives 
 
The overall aim was to determine whether capsules of Phela made for traditional use 
were of suitable quality to use in clinical trials. 
 
The specific objectives of the study were to: 
a) Establish (from literature) a series of criteria and specifications that are 
appropriate to establish the pharmaceutical quality of plant-containing 
capsules such as Phela,  
b) Assess the pharmaceutical characteristics of the finished Phela capsules,  
c) Assess the pharmaceutical characteristics of the ―formulated‖ Phela raw 
material, and 
d) Provide a certificate of analysis for the finished capsules.  
3.2. Hypotheses 
 
It was hypothesized that,  
Firstly, the capsule dosage form of Phela plant material would meet most of the general 
pharmacopoeial quality specifications, 
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Secondly, plant material contents of Phela capsules would be rapidly dissolving and 
meet the BP specification of 75 % of the extractable plant material dissolving in the 
acidic solution at pH 1.2 within 45 minutes, and  
 
Thirdly, the Phela plant materials contain flavonoids-like compounds that will be 
susceptible to degradation and may be suitable as marker compounds to monitor the 
stability Phela capsules during storage.  
3.3. Study approach 
 
 
To realize the above objectives the following were done: 
 
3.3.1. Establishment of a list criteria and specifications for pharmaceutical 
quality of plant material containing capsules  
 
Information provided by pharmacopoeia and regulatory agencies e.g. (BP, EMEA, 
WHO, etc) via internet was to be searched and assessed for criteria that may be used 
to establish the pharmaceutical quality of Phela. The information provided by the BP 
comprises of a series of monographs, each detailing mandatory standards for active 
substances, excipients and formulated preparation, together with supporting general 
notices, appendices (test methods, reagents, etc.) and reference spectra (BP, 2009). 
The United State Pharmacopeia (USP), nor the Japanese Pharmacopeia (JP) or the 
German Pharmacopeia (GP) were not used because most of the information provided 
in the BP would be exactly the same. Most of the information provided by EMEA 
relates to the conclusions reached by the European Medicines Agency's scientific 
committees following their procedures for evaluating the quality, safety and efficacy 
of medicines (EMEA, 2010). The WHO was chosen because of worldwide 
recognition for regulation of quality control of herbal medicines and the work of 
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WHO in supporting the preparation of model guidelines in this field, have been 
helpful in strengthening recognition of their role in health care ( Zhang, 1998).   
3.3.2. Assessment of the pharmaceutical quality of the finished Phela capsules 
 
Because the Phela capsules had already been manufactured by the time this present 
study commenced, the first step in the evaluation of the pharmaceutical quality of 
Phela was to focus on the manufactured Phela capsules. For this, the set of tests, 
methods and specifications arrived at in part 3.3.1 was to be used. The capsules were 
assessed specifically for their organoleptic characteristics, uniformity of weight, 
moisture content, dissolution profile and stability using pharmacopoeias methods.  
3.3.3.  Assessment of the pharmaceutical quality of the “formulated” Phela raw 
materials 
 
Because the Phela capsules contain a mixture of 4 different plant raw materials, each 
of which will affect the quality of the final Phela product, the pharmaceutical quality 
of each of the raw material powders and the mixture was also evaluated. Specifically, 
the physicochemical properties of the individual and the final formulated Phela raw 
material was assessed using the methods and specifications suggested by the 
guidelines discussed under 3.3.1. From the results the rational and appropriateness of 
the formulation and manufacture of these capsules could be assessed.  In this study, 
the generally used or suggested characteristics i.e. organoleptic features, flow 
properties, ash values, moisture content, contaminant (microbial, heavy metal, 
pesticide) levels, particle size, HPLC fingerprint, aqueous solubility and stability were 
determined using pharmacopoeia methods. 
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3.3.4. Determination of stability profile of Phela capsules 
 
 
The final step in this study was to determine the stability profile of the manufactured 
Phela capsules.  For clinical trials, the capsule dosage form of Phela should remain 
stable over a suitably long period and this can be determined by monitoring the level 
and integrity of selected chemical constituents of the herbal preparation over time. In 
this study, HPLC chromatographic fingerprints of the Phela material were generated 
and analysed.  As marker compounds for the stability assessment flavonoids were 
chosen because of their known abundance in these plants (Treutter, 2006), their known 
ability to cause pharmacological effects relevant to Phela (Ratty, et al, 1988) and their 
chemistry and degradation potential (Andersen, 2006) and their easy, sensitive and 
reliable detection by UV spectrophotometer. Finally, the HPLC method of assay was 
chosen because it is currently the most frequently used separation technique, and is 
capable of resolving complex chemical mixtures including the crude extract of 
traditional medicines (Ye, et al, 2006). 
3.3.5. Compilation of certificate of analysis  
 
A certificate of analysis (CoA) is a list of analytical tests, acceptance criteria, and 
results obtained on a specific product (USP, 2009) and forms an important part of any 
manufacture and quality assurance programme. Because the Phela capsules were 
intended for a clinical study, a CoA was required (WHO, 2005b). In this study, the 
CoA was compiled from the results obtained in the pharmaceutical analysis of various   
batches of raw materials and the herbal capsule dosage form as described under 
3.3.2.to 3.3.4.  
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Chapter 4 
 Methods 
 
 
 
In this chapter, the process used to select the criteria and specifications that can be 
applied to assess the pharmaceutical quality of a herbal product such as Phela capsules 
are presented. In addition, the materials, equipment, methods and procedures used to 
evaluate the pharmaceutical quality of the finished Phela capsules are presented. 
4.1. Chemicals and equipment  
 
The following chemicals were used: 
Acetonitrile, water and methanol (HPLC-Grade, Burdick & Jackson, Cape Town, 
South Africa); double distilled water (Fi-streem; England); hydrochloric acid (32% 
w/w, Analar grade, Cape Town, South Africa)  ―KIMIX‖; potassium dihydrogen 
phosphate (KH
2
PO
4 
) 
  
Anala- R
®
 (99.5-100.5%). Hard vegetable gelatine capsules (Size 
0; Colour: Yellow and Orange, Cape Town). 
 
The following equipment was used: 
 
Oven (figure 4.1., Model P.A Luthbert & C0, South Africa); milling machine (figure 
4.1., DCE Donaldson Limited, England); Automated capsule machine (figure 
4.1.,―SCF-10‖, China), Balance:- ―OHAUS‖ GA110 ―Mettler‖ AJ 100; 0.45µm HV 
DURAPORE
®
 MEMBRANE FILTERS; 5 ml syringes (PVA) ―Promex‖; Dissolution 
apparatus:- ―VanKel‖ VK 700;  UV-Vis Spectrophotometer:- ―Hitachi‖ U-3200; 
microscope, light:- ―Nikon Abbe 1.25‖ with an Olympus eyepiece; Sieve Shaker 
(Endecott Sieve Shaker, E.F.L. 1mk11, Endecotts (Test Sieve) Ltd, London, England);  
Sieves (Incorporating Madison Test Sieves (Pty) Ltd. Republic Of South Africa); 
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Mechanical Tapping Device (Chadwell Heath Essex, England); The HR73 Halogen 
Moisture Analyzer (METTLER TOLED, South Africa); Ash machine (Lasec, South 
Africa) HPLC system:- ―Agilent 1100 Series‖ fitted with: an Agilent 1100 Series 
quaternary pump, an Agilent  1100 series Diode Array and  Multiple wavelength 
detector;  HPLC column: (XTerra ® 5μ C-18, 4,6 x 150 mm, reversed-phase;  
Computer program in data-analysis:- Graph Pad PRISM ―Version 5.00‖   
   
 
Oven  Milling Machine Automated  Capsule 
Machine 
 
 
  
 
Figure 4. 1: Manufacturing Equipments 
 
 
4.2. Methods and procedures 
 
The following methods and procedures were used. 
 
4.2.1.  Selection of criteria, specifications and test methods for pharmaceutical 
quality of plant containing capsules 
 
Information provided by pharmacopoeia (e.g. BP, etc) and various regulatory 
authorities (e.g. EMEA, WHO, etc) via literature and the internet was searched and 
assessed for criteria and specifications that may be used to determine the 
pharmaceutical quality of the Phela capsules. Search terms like “guidelines for 
assessment for herbal medicines”, “quality control parameters for herbals’’, 
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“specification for herbal drug preparations” and “acceptance criteria of herbal 
medicines” were used to look at the sites and locate the specifications, i.e. analytical 
test, method and accepted tolerance limits, which were generally advocated to assure 
quality of herbal preparations.  The internet search was conducted between the months 
of August to September 2008 and two websites, viz. that of the European Medicines 
Agency (EMEA, 2004) and the World Health organization (WHO, 2000). 
 
A summary of all the test procedures, methods, criteria and specifications found was 
drawn up and from this a list those procedures, etc that were deemed appropriate for 
the evaluation of the Phela capsule was compiled.  
4.2.2. Manufacture of Phela capsules 
 
Phela capsules containing the combination of four plants i.e. RM, CG, PT and S that 
were collected by IKS MRC in different regions of South Africa were manufactured. 
The fresh plant materials were collected in July 2008 After collection the plant 
materials were separated from earthy and other foreign material, washed with distilled 
water, the leaves, stems and roots separated from the other portions of plant material 
and dried at 300C in the industrial oven (figure 4.1) until each part  retained a constant 
weight. Generally the individual Phela plant materials were reduced to one fourth of 
its weight upon drying.  After this, each part (i.e. leaves, etc) was ground into a fine 
powder using an industrial milling machine (figure 4.1). The Phela mixture was then 
made up by mixing the four plants i.e. RM, CG, PT and S (and mainly the roots) in a 
ratio of 1:1:1:2 parts, respectively, and capsules of the mix prepared using an 
automated capsule machine (figure 4.1). Finally, the finished capsules were cleaned 
by polishing them and then placed in suitable airtight containers. In this study the final 
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capsules, the Phela mixture as well as the dried powder of the individual constituent 
plants were pharmaceutically evaluated.   
 
4.2.3. Determination of the pharmaceutical quality of Phela capsules 
 
The pharmaceutical quality of the capsule contents and the capsules itself were 
evaluated.  
 
4.2.3.1. Determination of organoleptic properties of Phela capsule and contents   
 
 
To determine the organoleptic features of the capsule the appearance, shape and 
dimension of the capsule as well as the odour, colour and taste of the dried mixed and 
individual constituent powders of Phela were characterized using the natural sense 
organs (i.e. by eye, nose and tongue). This was done to establish a few key 
identification characteristics for the capsules. For the physical features, we looked at 
the material, particle size, texture and the strength of the particles. 
4.2.3.2. Determination of particle size and shape of Phela powders 
 
 
Sieve and microscopic methods are the commonly used methods to determine particle 
size and shape and were used to determine these for the materials used in this study. 
In this case, the British Pharmacopoeia (BP, 2000) methods were used to determine 
the fineness, particle size and particle shape of the Phela powder mixture and the 
individual constituent plant powders. For this sieves No’s 500, 355, 180, 125, 90 and 
0 were netted in order of decreasing aperture size, and a receiving pan closely fitted at 
their bottom. An accurately weighed amount (about 10.0 g) of samples of the Phela 
powders were  placed evenly upon the top-most sieve, the sieve arrangement shaken 
using the mechanical shaker until sifting was practically complete (around 40 
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minutes). Then, a soft cloth hairbrush was used to gently dislodge any powder 
material entrapped within the sieve openings. Thereafter the powder materials 
retained on each sieve size were weighed to the nearest 0.1 g and the proportion of 
powder materials retained on each sieve calculated as percentages of the total feed. 
These values were then compared with the BP specifications (BP, 2000)  to establish 
the fineness classification of each powder.  
 
To determine the shape of the particles of the mixture and individual powders a 
microscope was used to observe the particle shape and measure the size. The length 
and breadth of a selection of the particles in the view was measured with the 
micrometer, the readings recorded and the degree of sphericity calculated using the 
following equation  
 
N = L/B   equation   4.1 
 
 
Where: N = the degree of sphericity, L = particle length and B = particle breadth.  
 
 
4.2.3.3. Determination of the density of Phela powders 
 
 
To determine the density of the Phela powders a tester that essentially consists of a 
graduated cylinder placed on the tester platform was used (figure 4.2). In this 
apparatus a tapping action is generated by a camshaft, which lifts the platform and 
allows it to drop back to its original position. The normal speed of 100 taps per minute 
was used and taps were applied until a maximum packing condition was achieved. For 
the actual study, each powder was passed through the 710-micron sieve in order to 
break up agglomerates. Then it was weighed and poured, via a funnel, into a 
graduated cylinder. The volume of the powder was measured and the loose bulk 
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density calculated by dividing the weight of the powder by this volume. Thereafter, 
the level of powder in the graduated cylinder was checked after every 10 taps till there 
was no further reduction in the level. This was taken as the tapped volume which was 
used to calculate the tapped density. The measurements were done in triplicate for 
each Phela powder and an average value calculated. From the loose-packed and 
tapped densities, Carr’s compressibility index was calculated using the following 
equation (Thalberg, et al, 2004).  
 
HR= TD/BD     equation  4.2 
Where HR = the Hausner ratio, TD = the tapped density and BD = the loose-
packed bulk density of the powder. 
 
 
 
 
Figure 4. 2: Apparatus for density measurement  
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4.2.3.4. Determination of flow properties of the Phela powders 
 
To assess the flow properties of the Phela powders the angle of repose for the Phela 
mixture and individual constituent plant powers were determined as follows. About 
10 g of sample powder was placed in a glass cylinder that is open at both ends (figure 
4.3). The cylinder was then slowly and even lifted allowing the powder to freely run 
out the bottom end of the cylinder unto a flat surface forming a small pile of powder. 
Care was taken not to impose any stress on the powder in the cylinder and excess 
powder was removed from the cylinder. The height and radius of the heap were 
measured and the angle of repose calculated using the following equation 
 
                                       tan θ = h/r       equation  4.3
   
where θ = the angle of repose, h = height of the conical mound (cm) and r  = the 
radius of the conical mound of powder (cm) (Chandira, et al, 2010). Triplicate 
readings were made for each of the powders and the average reading calculated and 
recorded. 
 
 
 
Figure 4. 3: Apparatus for measuring angle of repose.   
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4.2.3.5. Determination of total ash values of Phela powders 
 
For the total ash testing, 2 g of the dried Phela plant or mixture powder material was 
heated in a tared crucible at 450 
0
C in a furnace until they were free of carbon (by 
checking color change).  For those for which a carbon-free ash could not be obtained 
in this way, hot water was poured over the charred mass, the mixture filtered on 
ashless filter paper and the residue on the filter paper incinerated at 450 
0
C. Thereafter 
the powders were cooled, weighed and the percentage of ash calculated with reference 
to the mass of the air-dried drug. 
 
For the acid-insoluble ash testing, the total ash of the relevant  Phela powder was 
boiled for 5 minutes with 25 ml of 2M hydrochloric acid, the insoluble matter 
collected on an ashless filter paper, washed with hot water and then ignited and heated 
at  450 
0
C. Finally, the remaining ash was weighed and the percentage of acid-
insoluble ash determined with reference to the mass of the air-dried drug. The 
individual powders were subjected to the same procedures and the results obtained 
were compared. 
 
4.2.3.6. Determination of the moisture level of the Phela powders.  
 
 
 The moisture levels of the Phela capsule contents and individual powders were 
determined using a Halogen Moisture Analyzer HR73. The analyzer consisted of a 
halogen-heating unit, a sample plate and an electronic weighing balance and works on 
the thermogravimetric principle i.e. the moisture analyzer determines the weight of 
the sample at the start, the integral halogen-heating module then quickly heats the 
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sample and the moisture vaporizes. During the drying process, the instrument 
continually measures the weight of the sample and displays the reduction in moisture.  
 
 
 
 
    Figure 4. 4: HR73 Halogen moisture analyzer. 
 
To determine the moisture level of the Phela powders six replicates of one gram of the 
individual powders and Phela mixture was placed on the balance plate, the analyzer 
started and the apparatus allowed to automatically calculating the weight of the 
moisture, from the following formula. 
 
Moisture weight = Initial weight (Wet mass) – Final weight (Dry mass) - equation 4.4 
 
 
4.2.3.7.  Determination of the water-soluble extractable fraction of Phela 
powders.                      
 
 
To determine the proportion of extractable fraction of the Phela mixture and 
individual powders, about four grams of each powdered material was accurately 
weighed in a conical flask, 100 ml of water added and the mixture macerated for 6 
hours while shaking frequently Thereafter, the mixture was allowed to stand for 18 
hours before it was filtered and approximately 25 ml of the filtrate was transferred to a 
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tared flat-bottomed dish and evaporated to dryness at 105 
0
C for 6 hours. The residue 
was then cooled in a desiccator for 30 minutes, and weighed immediately. The 
proportion of extractable matter was determined by subtracting the weight of the 
residue from the total powder weight and expressing it as fraction of the total powder 
weight. The results obtained for the powder mixture was compared with that for the 
individual plants. 
 
4.2.3.8. Determination of microbial contaminants of Phela powders. 
 
 
 
To determine the level of microbial contamination of the Phela mixture, 10 g of 
samples of the individual powders and mixture were packed into sealed brown glass 
containers and subjected to the following microbial level tests: total microbial activity 
(TMA) or total viable count, Escherichia coli count, yeast and mould count, 
Salmonella count and Enterobacteriaceae and other Gram-negatives counts. These 
tests were done by Swift Microlaboratories, Cape Town using standard procedures for 
microbial testing. Finally, the level of microbial contaminants obtained was assessed 
according to the specifications set by WHO (WHO, 2007). 
4.2.3.9. Determination of heavy metal contaminants in the Phela powders. 
 
 
To determine the levels of heavy metal and pesticides, the Phela mixture and 
individual dried powders were subjected to the following pesticide and heavy metal 
level tests done by the South African Bureau of Standards (SABS) Laboratories, Cape 
Town and MARLAB, Cape Town: pesticides - organophosphate, organonitrate, 
organochloride and N-methyl carbamate and heavy metals - lead (Pb), cadmium (Cd), 
mercury (Hg), arsenic (As), nickel (Ni) and chromium (Cr).  
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4.2.3.10. Determination of HPLC fingerprints of the Phela powders.  
 
 
An Agilent 1100 HPLC system (Agilent Technologies, Palo Alto, CA, USA) 
comprising a quaternary solvent delivery system, an on-line degasser, an auto-
sampler, a column temperature controller and photodiode array detector coupled with 
an analytical workstation was used to generate chromatographic fingerprints of the 
Phela powders. An Agilent XTerra ®MS C18 reversed-phase column (5 μm, 
150 mm × 4.6 mm) and an Agilent Zorbax Extend C18 guard column (5 μm, 
5 mm × 4.6 mm) maintained at 40 °C were used. 
 
The sample solution was prepared by extracting 10 mg of dried Phela plant material 
with 10 ml of methanol and distilled water (50:50 v/v). The solution was sonicated for 
15 minutes, centrifuged at 1000 rpm for 30 minutes, the supernatant collected and 
evaporated to dryness under a gentle stream of nitrogen at room temperature. The 
extracted material was re-dissolved into 5 ml water and acetonitrile (50/50 v/v) and 
the sample solution filtered through a 0.45- μm filter membrane before HPLC 
analysis. The sample solutions for the four individual plant materials and the Phela 
mixture were prepared in the same way and 20 μl of the extracts were injected on 
column. 
 
Elution of the solute peaks were achieved with a  mobile phase consisting of water-
formic acid (A; 100:0.01, v/v) and acetonitrile (B) pumped at flow rate of 1ml/min 
and the following gradient, viz. initial condition of solvents A : B of 50:50 v/v; 
linearly changed to 40:60 v/v at 10 min and then to 20:80 v/v over the next 
20 minutes. The detector wavelength was set at 300 nm and the chromatographic 
fingerprints of Phela and individual plant materials obtained were compared (in terms 
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of number, retention times and area percentage). The more prominent peaks (in terms 
of peak size and presence in the individual plant powders) were identified and 
subjected to spectral analysis to try and identify those with possible flavonoid spectral 
characteristics.  
4.2.3.11. Determination of uniformity of weight of the Phela capsules.  
 
The British Pharmacopoeia (BP, 2000e) method was used. According to this method 
not more than two of the individual weights (masses) of the capsules must deviate 
from the average weight (mass) by more than 7.5 % and none of the deviates by more 
than twice that percentage.  
 
To determine the uniformity of weight of the manufactured capsules and its content 
twenty capsules were randomly selected from each of the manufactured batches. Each 
capsule was weighed and then completely emptied of its contents, the empty shells 
brushed to remove any remaining particles, and the empty capsule reweighed.  The 
mass of the capsule contents was calculated by subtracting the mass of the empty 
capsule from the initial mass of the full capsule. The values for the 20 capsules were 
averaged. The percent deviation calculated and the results compared to the British 
Pharmacopoeia (BP, 2000) specifications. 
 
4.2.3.12. Determination of the dissolution profile of Phela capsules.  
 
 
The British Pharmacopoeia (BP) basket method (I) was used to determine the 
dissolution profile of the Phela capsules. Approximately 900 ml of buffer solution at 
pH 1.2 was used as dissolution medium to simulate dissolution in the stomach. The 
solution was degassed with helium gas before being introduced into the vessels in the 
dissolution apparatus and the apparatus allowed to warm up to 37±0.5 
0
C in the water 
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bath until a constant temperature was reached. One capsule was placed in each dry 
basket, the basket lowered into position and the apparatus immediately started at the 
rotation speed of 100 rpm.  
 
At various time points, viz. at 0, 15, 30, 45, 60, 55 and 120 minutes after start, 5 ml 
samples of the medium was withdrawn from a point halfway between the surface of 
the dissolution medium and the top of the rotating basket and not less than 10 mm 
from the wall of the vessel. The 5 ml withdrawn was immediately replaced with 5 ml 
of the buffer solution. The sampling probes were fitted with in-line 0.45 μm filters so 
that filtered samples were obtained. The UV absorbance of each sample was read at 
280 nm (against a blank reference consisting of just the medium).  
 
The sample giving the highest reading at 280 nm or the one at 120 minutes (with clear 
dispersion of the capsule contents) was taken as the 100 % released dissolved sample. 
The percent material dissolved at each time point was calculated and the average 
percentage material dissolved for the 6 Phela capsules at each time pointed plotted. 
From the graph, the time taken for 70 % of the capsule contents to dissolve was 
determined.  
4.2.3.13. Determination of the stability of Phela capsules. 
 
For this study, the manufactured Phela capsules were stored with packaging under one 
condition, viz. 40 ± 2
0
 C and 75 ± 5 % relative humidity (RH) in a climate chamber 
(labcon). Some capsules were stored at 40°C and 75 % relative humidity (at site A) 
and  some at 25
o
C and ordinary room level relative humidity (at site B) and some at 
5
0
C and 70 % relative humidity (at site C, in a desiccator).At the start and every two 
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weeks samples of capsules were taken from each site of the storage condition and 
assessed for organoleptic properties and physical properties (i.e. gross physical nature, 
colour and odour of the powder content and overall size, shape and appearance of the 
capsule) and the level of selected markers.  
 
The same HPLC conditions (see section 4.2.3.10) were used to assess the stability 
profile levels of Phela capsules, except that kinetex column was used. The spectrums 
of Phela capsules were compared in terms of retention time and peak heights after 24 
weeks of storage.   
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Chapter 5 
 
Results and Discussion 
 
In this chapter, the results obtained during the investigation of the criteria and 
specifications that may be applied to determine the pharmaceutical quality of herbal 
capsule dosage forms and their use to assess the pharmaceutical quality of Phela 
capsules are presented and discussed. 
 
5.1. Selection of criteria, specifications and test methods for pharmaceutical 
quality of plant-containing capsules. 
 
The attributes, specifications, tests and test methods that are recommended by the BP, 
EMEA and WHO for the control of the quality of herbal products were reviewed and 
the results obtained are summarized in table 5.1. From this, a set of criteria, 
procedures, etc that were deemed appropriate for the evaluation of the Phela capsule 
was compiled. 
 
Table 5. 1:  A selection of criteria, tests, test methods and specifications for pharmaceutical 
quality of herbal dosage forms    
 
Assessment 
criteria 
 
Tests Method Specification 
(Tolerance limit) 
 
Raw material of herbal products 
 
Physical attributes 
 
Organoleptic 
features (odour, 
colour & taste) 
 
Visual, Olfactory Consistency of  
odour, taste & 
colour 
 Macroscopic 
features (size and 
shape) 
as per  BP 
2000
 and 
WHO 
Must conform to 
herbarium 
reference material  
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 Microscopic  as per  BP 
2000
 and 
WHO 
Must conform to 
herbarium 
reference material. 
 
Chemical identity Chemical features 
presence &/or 
level of marker  
TLC, HPLC or 
other 
internationally 
recognized 
methods 
 
Presence and/or 
exact level of 
markers 
Quantity of plant 
active(s)   
Level of marker 
chemical 
constituent  
Quantitative by 
GC, HPLC, etc  
 
90-110% of label 
claim 
Microbial 
contamination 
Presence & level 
of contaminating 
fungus ( yeast and 
mould) 
 
Microbial test as 
per BP
1993
, EMEA 
2000
, WHO 
2007
 
< 1 X 10
4 
 
CFU/g or ml 
 Total Aerobic 
Count 
Microbial test as 
per BP
1993
, EMEA 
2000
, WHO 
2007 
 
< 1 X 10
5
 
CFU/g or ml 
 Escherichia coli Microbial test as 
per BP
1993
, 
EMEA
2000
, WHO 
2007
 
Absent 
 
 Salmonella spp. Microbial test as 
per BP
1993
, 
EMEA
2000
, WHO 
2007
 
Absent 
 
 Staphylococcus 
aureus 
Microbial test as 
per BP
1993
, 
EMEA
2000
, WHO 
2007
 
Absent 
 Pseudomonas 
aeruginosa 
Microbial test as 
per BP
1993
, 
EMEA
2000
, WHO 
2007 
 
Absent 
Heavy metal 
contamination 
Level of Arsenic Chemical test as 
per BP
1993
, EMEA 
2000
, WHO
 2007 
 
< 0.14 μg/kg 
b.w /day 
 Level of Cadmium 
 
Chemical test as 
per BP
1993
, EMEA 
2000
, WHO 
2007
 
< 0.14 μg/kg 
b.w/day 
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  Level of Lead 
 
Chemical test as 
per BP
1993
, EMEA 
2000
 , WHO 
2007 
 
< 0.09 μg/kg 
b.w/day 
  Level of total 
Mercury 
 
Chemical test as 
per BP
1993
, EMEA 
2000
, WHO 
2007 
 
< 0.29 μg/kg 
b.w/day 
Pesticide 
Contamination 
Level and or 
presence of 
Pesticides (e.g. 
DDT) 
 
Chemical test as 
per BP, EMEA, 
WHO 
2007
 
Conforms to 
Pharmacopoeial 
limits 
Mycotoxins 
Contamination 
Presence &/or 
level of  
Mycotoxins 
Chemical test as 
per BP, EMEA, 
WHO 
2007
 
 
Aflotoxins < 20 
ppb 
Herbal products/dosage forms 
 
Uniformity of 
Dosage form 
Mass or content 
variation 
 
As per BP 
20006
 The % RSD for 
capsules is ±7.5% 
 
Dissolution profile Percentage 
released in set time 
performance test 
As per BP 2000
5
.  75% of label claim 
to be released in 
45 minutes of 
dissolution testing.  
 
Stability  Shelf life; expiry 
date of product; 
degradation half-
life of chemical 
marker 
compounds level 
of (active or 
impurity).  
as per , EMEA 
2007
, WHO 
1996
 
N/A 
 
 
Only the information provided by the one pharmacopeia and  two agencies , viz. the 
European Medicine Agency (EMEA, 2006), the World Health Organization (WHO, 
1998) and the British Pharmacopoeia (BP, 2000) were looked at for the compilation 
of the above table and for the purpose of this study the BP, EMEA and WHO will 
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collectively be referred to as the agencies. These agencies seem to advocate similar 
criteria, tests, methods and tolerance levels (i.e. specifications) for the control of the 
quality of both pharmaceutical and herbal products. For the above table the 
assessment criteria for quality control of herbal medicine were separated into those 
focussing on the raw material attributes e.g. physical attributes, chemical identity, 
microbial, heavy metal, pesticides, etc contamination and finished product e.g. 
dissolution, stability, content uniformity (in terms of quantity of plant active), etc.   
 
According to the requirements of the 3 agencies a list of the physical attributes of the 
raw material (and finished products and/or their contents) must be compiled based on 
the organoleptic and micro- and macroscopic physical features. For this the senses 
(i.e. visual or olfactory) and a variety of tests (e.g. using a BP method) can be used.  
For herbal products the tolerance level for these attributes must typically conform to 
that of herbarium reference material e.g. be consistent in odour, taste and colour to the 
latter.  
 
Another important characteristic for quality control is the chemical identity of the 
herbal material or product. For this a test for the level or presence of marker chemical 
compounds found in the material can be done using internationally recognised 
methods, such as thin layer chromatography (TLC), high performance liquid 
chromatography (HPLC), etc. Some of the methods are more preferred than others. 
For example HPLC have advantages of speed of assay, automation, improved 
accuracy and precision over TLC and this is why it is nowadays more frequently 
employed in quality control. Finally, the specification level for this chemical identity 
 50 
attribute of herbal material typically should indicate the presence or exact level of a 
chemical marker(s).  
 
Probably the most important quality criterion for herbal products might be the level of 
active constituents they contain. Various quantitative analysis methods i.e. HPLC, 
GC, etc can be used to identify and obtain the levels of chemical marker compounds 
in the plant material that may or may not be plant active(s). For quality control the 
tolerance limits for the quantity of active ingredients in normal pharmaceuticals is 
typically set at 80 % to 120 % (or some narrower range) of the label amount (esp. if 
tested by HPLC). The same can thus be advocated for herbal products. Thus for 
herbal products the levels of target marker(s) or active constituent(s) should be well 
within a range set as the acceptance criteria for each marker(s).  
 
Apart from the constituent chemicals of the herbal material the presence/absence of 
extraneously introduced materials such as microorganisms, heavy metals toxins, 
pesticides and adulterants that could end up in the herbal materials is also an 
important determinant of the quality of herbal material. All three agencies recommend 
that herbal materials be tested for a list of microbial contaminants, which include E. 
coli, Salmonella spp, Staphylococcus aureus, fungi and molds, etc, using typical 
methods also given in or by the BP, EMEA or WHO. Typically the quality control 
specification with respect to microbial contamination is based on the level of 
contaminants allowed to be present e.g. the colony levels of yeast and mould should 
be less than 1 X 10
4   
CFU/g or ml and that for total aerobic counts < 1 X 10
5 
CFU/g or 
ml) or the complete absence of the contaminant e.g. E. coli, Salmonella, etc. should be 
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absent upon testing. The BP, EMEA and WHO generally advocated the same 
microbial contamination tolerance levels.  
 
For heavy metal contamination such as lead, mercury, etc the BP, EMEA and WHO 
generally advocate the same tests, test methods and the tolerance levels. In addition 
there are tests for pesticides and mycotoxins (e.g. test for the presence of DDT and 
aflotoxins) required to confirm the quality of herbal products. Specifically, the levels 
of mycotoxins (e.g., aflotoxins) should be below 20 ppb and the presence of pesticides 
must conform to specific pharmacopoeial limits. Overall, the three agencies agree on 
the set of criteria and methods and specifications that are required to confirm the 
quality of an herbal product as far as contamination is concerned. The issue of 
intentional adulteration of herbal products with pharmacologically active 
pharmaceutical products is a related issue of quality but was not addressed in this 
project.   
 
As far as dosage forms of herbals are concerned, the first important quality criterion 
for an herbal product should be that of mass and content uniformity. The test for mass 
uniformity entails is based on the use of a representative sample of 20 units that are 
individually weighed, the average mass determined and the specifications that not 
more than two of the individual masses deviate from the average mass by more than 
one percentage deviation (PD) and none deviates by more than twice that percentage 
(Martin, et al, 1998). According to the British Pharmacopoeia (BP, 2000f),  the limit 
on the acceptable deviation in weight from average for capsules is ±7.5 % and the 
limits on the amount of content in the capsules 90 % to 110 % (Ma, 2006).   
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Another important criterion of quality of especially herbal products is the rate at 
which it or its marker compounds dissolve i.e. its dissolution profile (BP, 2000e). The 
dissolution test and dissolution specification criterion is thus important for the quality 
control of herbal products. The test requires the determination of the percentage 
release of the active constituent into the dissolution medium over time typically using 
a method and specification criterion given in the BP. For instance, the tolerance limit 
set by the BP for a rapidly dissolving product is that 75 % of the label amount has to 
be released within 45 minutes. Once dissolution specifications are set, the 
pharmaceutical product or herbal product should, as a mark of continued quality, 
comply with those specifications throughout its shelf-life. 
 
Lastly, the EMEA and WHO recommend that a profile of the stability of the herbal 
product be provided (EMEA, 2006b; WHO, 1996). Appropriate stability test(s) should 
be used to determine the levels and degradation half-life of chemical marker 
compounds (active or impurity) and calculate the shelf life and expiry date of the 
product(s). Typically the methods used to establish the dissolution profile and/or 
quantitative levels of active constituent(s) can be used in these stability tests. 
Presently, there are no formally recommended specifications available for the stability 
of herbal products in the EMEA, 2007 and WHO, 1996, but the limits that denote 
acceptable stability may be derived from the profile obtained when the herbal material 
was assessed in previous or pre-formulation studies. The stability tolerance limits 
need to include individual and total upper limits for impurities and degradation 
products.  Normally, in the case of conventional pharmaceuticals, impurities and 
degradation products in concentrations higher than 0, 1 % should be identified (MCC, 
2006) and possibly the same could apply for herbal products.  
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Overall, the review of the recommendations of the BP, EMEA and WHO on the 
quality control of herbal products, as summarised in table 5.1, provided useful 
information of quality attributes, test methods and specifications on which the quality 
profile of the Phela  capsules could be based.  It was consequently concluded that an 
assessment of the physical attributes, chemical identity and quantity of plant active(s), 
microbial and other contaminant levels, content and mass uniformity, dissolution 
profile and stability profiles of the Phela capsules and/or its contents should provide a 
good idea of the quality of the Phela capsules (suitability for use in clinical trial).  
5.2. Assessment of the pharmaceutical quality of Phela plant materials. 
 
5.2.1. Organoleptic properties of Phela raw material and capsule contents. 
 
The determination of organoleptic properties involves measurement of attributes such 
as capsule size, shape, colour, presence or absence of odour, taste, surface textures, 
physical flaws and consistency. In this study, the following organoleptic properties of 
the plant materials of Phela were assessed: physical appearance, odour and taste using 
the natural sense organs (e.g. eyes, nose, and mouth). 
 
The results of the assessment of the organoleptic characteristics of the individual 
powders and the final Phela mixture are given in table 5.2. The milled dried plant 
material of plant RM and CG had similar physical appearance, colour, taste and 
odour. Plant S powder was dark brown in color, had a characteristic odour and 
irregular shape and size particles and was bitter in taste while Plant PT powder was 
yellow in color, had a smooth soft texture, was extremely bitter in taste and   
medicinal odour.    
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Table 5. 2: The organoleptic characteristics of individual powders and Phela mixture 
 
Characteristics  Plant RM Plant CG  Plant PT Plant S Phela 
 
Colour  
 
 
light brown light brown yellow dark 
brown 
 
Uniformly light 
brown 
Physical 
Appearance 
small particle 
powders. 
 
 
rough and 
brittle 
particle 
 
free-flowing 
 
small 
particle 
powders. 
 
 
rough and 
brittle 
particle 
 
free-flowing, 
small 
particle 
powders, 
 
 
smooth soft 
particle 
 
 
free-
flowing, 
 
large 
particle 
powders, 
 
 
even, 
rough 
texture  
particles 
 
 
non-
flowing 
 
small particle 
powder 
 
even rough and 
brittle particles 
 
free-flowing, 
 
Taste Bitter bitter extremely 
bitter 
 
bitter bitter 
Odour  characteristic 
plant odour 
 
characteristic 
plant odour 
medicinal 
odour 
senna 
odour 
characteristic 
medicinal 
odour 
 
Not surprisingly the entire mixture had light brown colour reflecting the organoleptic 
features of its components, even rough and brittle particles, a bitter taste and 
unpleasant odour. The features, especially the taste and colour, of the final Phela 
mixture may result in poor patient acceptability. Fortunately, the two characteristics 
were however masked by using a capsule dosage form that alleviated these unpleasant 
effects. 
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5.2.2. Particle size and shape of Phela raw material and final mixture.   
 
Sieve and microscopic methods are the commonly used methods to determine particle 
size and shape (BP, 2000). The results of the determination of the particle size of the 
Phela mixture and individual powders are given in appendix 1 and summarized in 
table 5.3 and figure 5.1.  
 
Table 5. 3: Percentage of Phela plant powder retained on each sieve size 
 
Sieve 
size(μm) 
Plant RM 
(%)  
Plant CG 
(%)  
Plant PT 
(%) 
Plant S 
(%) 
Phela 
(%) 
500 8.79 6.7 6.01 6.33 7.62 
355 8.7 8.67 7.68 15.63 9.61 
180 15.93 26.06 18.33 33.39 24.44 
125 8.8 14.2 17.22 11.05 8.27 
90 27.41 21.4 39.31 17.09 22.66 
0 25.86 15.84 5.94 11.84 20.96 
total 95.49 92.87 94.49 95.33 93.56 
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Figure 5. 1: Distribution of particle size of the Phela powders passing through different sieve 
sizes. Histogram of powders of plants (a) RM, (b) CG, (c) PT (d) S and (e) Phela 
mixture. 
 
It appears that the powder of plants RM and CG had a bimodal particle size 
distribution where as that for plants PT and S were perhaps more skewed to the left 
and right, respectively. Overall, the individual plants were non-uniform in particle 
size and so was the powder of the final Phela mixture. Based on the BP (2000) criteria 
the particle size of the powders was thus not gradable.  Such range in particle size 
may have an impact on the capsule manufacture, for example lead to non-uniform 
filling and variation in capsule weight and perhaps in variation of dissolution.  Since 
the powders contained a large proportion of large particles (i.e. approx 40 % > 355 
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micron) additional sieving and removal of these bigger particles before encapsulation 
may be another option to consider to ensure capsules of uniform weight and content.  
 
The results of the particle shape analysis are given in appendix 2 and in Table 5.4.  
 
Table 5. 4: Degree of sphericity for particles of Phela powders  
 
 
 
 
 
 
Generally, the numerical value for the degree of sphericity (θ) of a particle having the 
shape of a sphere is one (Wadell, 1932). Of the four plant powders, the particles of 
plant PT were essentially spherical (θ = 1.19 ± 0.63) but that of the other three plants 
and the mixture had distinctly elongated and non-spherical (θ > 3). The particles of 
the mixture was thus expected to have relatively small surface area and their 
elongated shape could have led to non-uniform filling of the capsule,  but additional 
grinding and sieving of the three plants or the mixture would, if needed, have 
remedied such problems. Overall, the non-uniform particle size and shape obtained 
was however not unexpected for the type of milling machine and plant material i.e. 
leaves, stems and roots, used. In contrast, for instance, when aqueous extract of plant 
material is used e.g. the Artemisia afra freeze-dried aqueous extract powder 
(Komperlla, 2004) and Leonotis leonorus (Ma, 2006), the particle size and shape 
obtained were much more uniform.  
Powder material Degree of sphericity (θ) 
Plant RM 3.38 ± 2.32 
Plant CG 3.60 ± 1.44 
Plant PT 1.19 ± 0.63 
Plant S 3.72 ± 1.88 
Phela 3.17 ± 1.78 
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5.2.3. The density, compressibility and flowability of Phela powders. 
 
Density measurements are methods commonly used to determine the flowability and 
compressibility of powders. The results of the density, compressibility and flowability 
tests are indicated in table 5.5. 
 
 
Table 5.5: Summary of pharmaceutical properties of the Phela plant and final mixture 
powders. 
  
 
 
The final mixture had a tapped density of 0.4 ± 0.001 and Carr’s compressibility 
index of 3.98 ± 0.97. These values are dependent on factors such as particle size, size 
distribution and shape. For instance, for the powders with large spherical particles, 
such as those of the plant CG, RM and S, a maximum packing condition is easily 
reached with fewer taps, while for the plant PT powder the mobility provided by the 
tapping on the segregating system would allow the small particles to rearrange to form 
   
Pharmaceutic
al property 
Plant powder 
Plant RM Plant PT Plant CG Plant S Phela mixture 
Tapped 
Density  
(n = 3) 
0.36 ±0.003 0.59 ±0.02 0.30 ±0.02 0.29 ±0.03 0.4 ±0.001 
Carr’s 
compressibility 
index (n =3) 
2.70 ± 0.82 6.39 ± 1.79 3.9 ± 1.32 4.62 ± 1.55 3.98 ± 0.97 
Angle of repose 
(
0
) (n = 10) 
39.233±3.85 39.41±1.85 35.91±3.24 38.16±4.59 37.92±1.28 
Total ash (%) 
(n = 10) 
6.78±0.41 4.23±0.18 6.73±0.16 3.56±0.14 5.80±0.1 
Moisture content 
level (%) (n = 6) 
9.29±0.31 8.58±0.43 9.31±0.06 10.29±0.53 9.77±0.08 
Water-soluble 
extractable 
fraction (%) 
(n = 6) 
39.61±4.74 77.98±5.28 43.18±1.69 32.79±2.87 47.43±3.80 
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the densest packing. The tapped density value for the mixture however suggested that 
this powder should not lead to inconsistent packing into capsules and should be easily 
compressible into a tablet dosage form. Moreover, the compressibility results 
suggested that the powder of the final mixture, as well as that of the individual plants, 
had excellent flowability (see table 5.6).  
 
Table 5. 6: Relationship between compressibility and flowability (Well, 1988) 
 
Compressibility index ( Carr’s 
index) 
Flow quality 
5-10 Excellent 
12-16 Good 
18-21 Fair to passable 
23-35 Poor 
33-38 Very poor 
>40 Very very poor 
 
 
The latter was confirmed by the angle of repose measurements (table 5.5) which 
showed that the powder of the final mixture (and the individual plant powders) was 
free flowing (and that of the individual plant powders fair passable) (see table 5.7).  
Taken together, the results thus showed that the final mixture powder had 
excellent/passable compressibility and flowability properties. If this had not been the 
case the addition of excipients such as the talc, silica, magnesium stearate, etc could 
have been considered to improve the flowability properties of the final mixture. 
Finally, the compressibility and flowability results are in agreement with that obtained 
on freeze-dried aqueous extract powder of the Artemisia afra (Komperlla, 2004).  
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Table 5. 7: Carr classification of powder flowability based on Angle of Repose (Well, 1988) 
 
Description Angle of repose 
 
Very free flowing    25-30º 
Free flowing      30-38º 
Fair to passable flow   38-45º 
Cohesive     45-55º 
Very cohesive   
 >55º 
 
 
5.2.4. Total ash values of Phela powders. 
 
Ashing involves an oxidation of the components of the products. The ash of any 
organic material is composed of their non-volatile inorganic components. Controlled 
incineration of crude drugs results in an ash residue consisting of an inorganic 
material i.e. metallic salts and silica (Siddique, et al, 2010). A high ash value is 
indicative of contamination, substitution and adulteration or carelessness in preparing 
the crude drug for marketing. Unwanted material from direct contamination such as 
sand or earth is immediately detected by considering the ash value.  
 
The results obtained for the total ash value determination of the plant powders are 
given in table 5.5. Since there are no other data or reference values for the total ash, 
acid-insoluble ash and sulphated ash tests of the four individual plants (e.g. in 
monographs, etc of the individual plants) and the final mixture the results obtained in 
this study were thus taken as standards for the batch of material.   
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5.2.5. The moisture level of the Phela powders.  
 
 
The moisture levels obtained for the individual powders are given in table 5.5. The 
level for the Phela mixture was 9.77±0.08 % indicating that the powder of the mixture 
was not particular hygroscopic and had been properly dried before manufacturing.  
The moisture content of the Phela mixture and the individual plant powders were 
comparable to that of M. longifolia aqueous extract powder (8.398±0.1357 %) 
(Haiqui, 2006) but this is the first data for the individual powders. The result should 
be useful for future reference when Phela capsules are made.  
5.2.6. The water-soluble extractable fraction of Phela powders. 
 
The results of the determination of water extractable matter obtained for the plant and 
final mixture powders are given in table 5.5. The Plant PT powder had the highest 
water extractability (77.98±5.28 %) plant S had the lowest (32.79±2.87 %) and the 
Phela mixture the average of the two (47.43±3.80 %). Because the mixture was 
extracted in water the extracted material is expected to be soluble and based on the 
descriptions given in table 5.8, to be soluble to very water soluble (BP, 2000). More 
important is the fact that the 47.43±3.80 % yield of water extractable material means 
that almost 50 % of the plant material is water soluble and would be found in the 
traditional liquid dosage forms of Phela. 
 
 
 
 
 
 
 
 
 
 
 
 
 62 
Table 5.8: Common descriptive phrases of solubility and the corresponding quantitative 
solubility ranges as per B.P (2000) 
 
 
5.2.7. Microbial contaminants levels of Phela powders. 
 
The microbial contamination test results for the four plant powders are given in the 
appendix 3 and summarized in table 5.9. No Staphylococcus. aureus,  Pseudomonas 
aeruginosa, Salmonella species and Escherichia coli were detected in any of the Phela 
powders and the microbial contamination testing results were all within the WHO 
specification (WHO, 2007).   
 
Table 5. 9:  Microbial results of plant powders and Phela mixture 
 
 
 
Descriptive Phrase Approximate quantities of solvent by volume for 
1 part of solute by weight. 
Very soluble less than 1 part 
Freely soluble from 1 to 10 parts 
Soluble from 10 to 30 parts 
Sparingly soluble from 30 to 100 parts 
Slightly soluble from 100 to 1000 parts 
Very slightly soluble from 1000 to 10,000 parts 
Practically insoluble more than 10,000 parts 
Plant 
powders 
Pseudomonas Staphylococcus E. coli Salmonella spp 
 
Plant RM Negative Negative Negative Negative 
Plant PT Negative Negative Negative Negative 
Plant CG Negative Negative Negative Negative 
Plant S Negative Negative Negative Negative 
Phela 
Mixture 
Negative Negative Negative Negative 
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5.2.8. Heavy metal and pesticides contaminants in the Phela powders. 
 
  
The results of heavy metal and pesticides level tests are shown in appendix 4 and 5, 
respectively. The Phela mixture on average contained <0.5 and 4.2 mg/kg of Cd and 
Pb, respectively. No traces of organophosphate, organonitrate, organochloride and N-
methyl carbamate pesticides were detected.  The heavy metal levels for Phela mixture 
were well within the limits specified by the WHO (2007) i.e. 10 mg/kg for Pb and 0.3 
mg/kg for Cd. Overall, as far as  heavy metal and pesticide contamination were 
concerned, the Phela powder complied with  the WHO specifications  and were thus 
safe for consumption. 
5.2.9. HPLC fingerprints of the Phela powders. 
 
A comparative study of chromatographic fingerprints of Phela powders was 
conducted. Copies of the individual chromatographic fingerprints of Phela powders 
obtained for plants S, CG, RM and PT are indicated in appendix 6 and that for the 
Phela mixture indicated in figure 5.2. A wavelength of 300 nm appeared to be the one 
where the most peaks for each plant material was obtained.  
 
All the peaks observed were first checked to see if they represented single or multiple 
compounds using the photodiode array detector and the HPLC system’s software (see 
figure 5.2). The Phela mixture had five distinct peaks (A to E), three of which showed 
reasonable resolution and two peaks, C and D, which overlapped. Although different 
solvent gradient systems were tried, it was not possible to separate the co-eluting 
peaks C and D. It was also not possible with the spectral analysis to conclusively 
prove that each of the peaks represented single compounds only, but except for peak 
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B, it is reasonable to assume that each peak represented either a single compound or 
mixture of structurally very similar compounds.  
 
Peaks A to D had distinct UV-absorbance maxima at 293.5, 292.1, 290.1 and 295.4 
nm respectively, while Peak E had a distinctive high intensity of absorbance’s at 
253.1 nm and low absorbance at 349.4 nm (figure 5.2E). The latter type of spectrum 
(i.e. absorbance maxima in 240 to 285 nm region – band II - and 300 to 400 nm 
region – Band I) is usually associated with that of flavonoids like that of 
sutherlandioside D (Avula, et al, 2010),  suggesting that at least peak E may be the 
result of the presence of one or more flavone type structures. The position of band I in 
flavones is between 304 – 550 nm while flavonols absorbs in the range of 352 – 385 
nm (MaleŠev, et al, 2007). The band II peak are generally assumed to be due to 
absorbance of benzoyl system ring A while band I is the results of absorbance due to 
the cinnamoyl system ring B (Bhat, et al, 2005). Further identification and analysis of 
the compounds represented by peaks A to E will however only be possible with other 
techniques such as LC-MS. Nevertheless these peaks (A to E) in the Phela HPLC 
fingerprint can still be a useful characteristic to use in the quality control of this plant 
medicine.  
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Figure 5. 2: HPLC fingerprint of Phela mixture eluted with acetonitrile/water-formic acid 
mixtures and ultraviolet spectra of five selected individual peaks (A-E). For the 
fingerprint UV detection at 300 nm was used and spectrum over 200 to 350nm.  
 
 
In addition to the above qualitative analysis, all the peaks having an area percentage 
greater than 1.5 of the total area and retention greater than 7 min were also identified 
and used for the comparison of the fingerprints and the results obtained are given in 
table 5.10 and appendix 6. As mentioned earlier, the Phela mixture had six peaks that 
met these criteria of having retention time > 7 minutes and area > 1.5%. 
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Table 5.10: Summary of main peaks in HPLC fingerprints of Phela materials. Only peaks having 
retention time > 7 min mins and area > 1.5% are recorded. 
 
 
Plant 
material 
Main Peaks 
(Retention time, Rt > 7 min and area > 1.5 %) 
Peak A Peak  B Peak  C Peak  D Peak  E Peak F Peak 
G 
Rt 
(min) 
Area 
(%) 
Rt 
(min) 
Area 
(%) 
Rt  
(min) 
Area 
(%) 
Rt 
(min) 
Area 
(%) 
Rt 
(min) 
Area 
(%) 
Rt 
(min) 
Area 
(%) 
Rt 
(min) 
Phela 
mixture 
7.3 1.5 7.78 2.9 11.05 5.62 12.68 3.54 13.16 3.51 14.21 3.5  
CG 7.29 0.9 7.77 3.2 11.04 6.05 12.68 3.51 13.75 5.9 14.21 4.7  
RM 7.27 1.7         (15.65) 1.2 16.53 
PT       12.69 -- 13.76 -- 14.21 ---  
S 7.36 4.6 (10.05) 2.6 (11.92)    (13.93) 3.2   16.55 
 
The fingerprint of the plant CG had six peaks  that also appeared in the fingerprint of 
the Phela mixture while that for plants RM and S had only one of these peaks in 
common with that of the mixture. The PT fingerprint had indications of presence of 3 
of the 6 peaks (A to F) but the areas did not meet the > 1.5 % inclusion criterion. It 
has been noted that there other additional peaks (10.05, 11.92, 13.93 and 15.65) 
minute which are not prominent in the final mixture. The fingerprints of plant RM and 
S each also contained at least one additional peak which was not evident or very 
prominent in the fingerprint of the final mixture (under the conditions used in this 
study). Collectively, this qualitative analysis suggested that the six peaks (A to F) in 
the fingerprint of the mixture reasonably reflected the possible presence (peak 
retention time and, possibly peak size) of the 4 individual constituent plants and might 
thus form a reasonable criterion on which the quality control of the Phela mixture 
could be based.  
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5.2.10. Conclusion on the Phela plant powders. 
 
 
Collectively, the results (from section 5.2.1 to 5.2.2) indicated that the Phela plant 
mixture powder was organoleptically, a uniformly light brown in colour, had a bitter 
taste and characteristic medicinal odour which could be masked by a capsule dosage 
form. The 4 plant powders had irregular shapes and sizes and the final mixture was 
not easily gradable in terms of particle size and shape. The four crude plant powders 
(RM, PT, CG, S) and the mixture had similar flow properties (i.e. angles of repose of 
39.233±3.85°, 39.41±1.85°, 35.91±3.24°, 38.16±4.59° and 37.92±1.28°, respectively) 
and acceptable moisture content levels (i.e. 9.28±0.31 %, 8.58±0.43 %, 9.31±0.06 %, 
10.29±0.53 % and 9.77±0.08 % respectively) which was unchanged in final mixture.  
The fraction of water soluble matter was very high for plant PT (77.99±5.82 %), low 
for plant S (32.79±2.87 %), RM (39.61±4.74 %), CG (43.18±1.69 %) and for the 
Phela mixture (47.43±3.80 %). The heavy metal, pesticides and microbial 
contaminant levels were well within acceptable WHO standards and the HPLC 
fingerprints indicated five compounds or peaks that could used to assess the quality of 
Phela mixture.  
 
The overall these results indicated that Phela powders could thus be easily 
compressed into a tablet dosage form and that the powders had a good flowability, 
which would make filling them into capsules non-problematic. Moreover, the 
contaminant levels were well within the generally accepted regulatory criteria and the 
capsules were thus be safe for consumption. Finally, an HPLC fingerprint containing 
6 distinctive peaks with the retention time > 7minutes and area percentage > 1.5 % 
was an appropriate quality control specification for the Phela mixture powder.  
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5.3. Assessment of the pharmaceutical quality of the finished Phela capsules.  
The finished Phela capsules were analyzed for uniformity of weight, dissolution 
profile and stability.  
5.3.1. Uniformity of weight of the Phela capsules.  
 
The results of the uniformity of weight of the Phela capsules determination are given 
in appendix 7. The full capsules on average weighed of 0.42 ±0.01 g, with RSD of 
2.38 % and contained 0.32±0.01 g of plant formulation (contents) with RSD of 3 %. 
The average deviations in weight for capsules were 2.801±1.45 %. According to the 
British Pharmacopoeia (BP, 2000e), the limit on the acceptable deviation in weight 
from average for capsules is ± 7.5 % and the limits on the amount of content in the 
capsules 90 % to 110 %. The afore-mentioned results thus indicated that the Phela 
capsules met the British Pharmacopoeia specifications. 
5.3.2. Dissolution profile of Phela capsules.  
 
 
The dissolution test of a herbal product such as Phela capsules measures the rate of 
release of soluble constituents from such dosage forms. In the present study the 
amount released and going into solution in the dissolution medium was measured by 
monitoring the UV absorbance of the solution at 280 nm at various times after 
exposure to the dissolution medium. From these readings the cumulative amount and 
percentage of Phela soluble ingredients released was calculated and plotted over time. 
The results of the dissolution studies on Phela capsules are given in appendix 8 and is 
summarised in figure 5.3. In the pH 1.2 dissolution medium the release and 
dissolution of the soluble ingredients of Phela was slow with 50.5 ± 6.76 % (n=6) of 
the Phela content dissolving in 45 minutes and 90.82 ± 2.17 % after 75 minutes.  
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Figure 5. 3: Dissolution profile of Phela capsules (n=6).  Dissolution conditions: basket 
method; 900ml pH 1.2 hydrochloric acid buffer; 37±0.5℃; samples quantitated 
by UV assay at 280 nm. 
 
 
Official dissolution specifications have been set for very few herbal products.  The 
USP 29, contain the dissolution specifications for some botanical products, e.g.  
ginger capsules - not less than 60 % of the content of 6-gingerol ( C17H26O4) capsules 
is dissolved in 60 minutes (USP, 2006); chondroitin sulfate sodium tablets - not less 
than 75 % of the labeled amount of chondroitin sulfate sodium is dissolved in 60 
minutes (USP, 2006); milk thistle capsule or tablets - not less than 75 % of the labeled 
amount of silymarin as silybin (C25H22O10) is dissolved in 45 minutes (USP, 2006) 
and glucosamine tablets  - not less than 75 % of the labeled amount of glucosamine 
(C6H13NO5) is dissolved in 45 minutes (USP, 2006). The EMEA proposes that a 
disintegration test may substitute for a dissolution test if the active ingredient is 
known to be highly soluble in aqueous media at pH values typical of the gastro-
intestinal tract (EMEA, 2005). On the other hand, the Food and Drug Administration 
(FDA) in their guidelines for dietary supplements leaves any specific requirements for 
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dissolution or disintegration unaddressed (FDA, 2007).  This overall lack of 
dissolution standards for herbal products may be partly due to the chemical 
complexity of botanicals (Jin, et al, 2007) and/or because few of these products are 
officially registered.  
 
In the present study, the Phela capsules exhibited substantially slow dissolution 
suggesting that they will only release soluble active ingredients slowly in the stomach.  
It must however be noted that the assay method used (i.e. UV absorbance at 280 nm) 
was not very specific and neither was a selective ingredient(s) monitored. Monitoring 
the dissolution of specific Phela ingredients and using a more sensitive and selective 
validated assay method such as HPLC may produce more specific data on which a 
quality control dissolution specification for these Phela capsules could be based.  
 
It must also be kept in mind that the dissolution profile of the Phela capsules may be 
quite different at pH 4.5 and 6.8. Thus the in vivo bioavailability or absorption profile 
of its active ingredients can not necessarily accurately be predicted from the present 
dissolution data. The present dissolution data is however most useful as a product 
quality or consistency indicator (e.g. to establish capsule uniformity and batch to 
batch consistency, etc) and the non-selective UV assay an inexpensive, convenient 
and easy method to use to establish/confirm that criterion. The present dissolution 
data is the first one of Phela and can thus be used to attain and monitor the 
consistency in the quality of the Phela capsules to be used in the proposed clinical 
trials on the herbal product. A dissolution specification of not less than 60 % of Phela 
content dissolved in 60 minutes appears to be appropriate for the Phela capsule (as for 
the USP specification for the ginger capsules). 
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5.3.3. Stability of the Phela capsules. 
 
 
Stability studies are designed to give an insight into the drug degradation mechanism, 
half-life (one-half the original concentration) and expiry date (t90, shelf-life) 
estimation (Álvarez-Lueje. 2005). The purposes of stability testing are to provide 
evidence on how the quality of a drug substance or medicinal product varies with time 
under the influence of a variety of environmental factors, such as temperature, 
humidity, and light, and to establish a re-test period for the drug substance or a shelf 
life for the medicinal product and recommended storage conditions (EMEA, 2007). 
For the present study, the selected chemical markers indicated as compound A to E in 
(Fig. 5.4) were used in the assessment of the stability of the Phela capsules.  
  
Two batches of Phela capsules were stored at room temperature and in the climatic 
chamber for six months, respectively. The results for the first batch are indicated in 
appendix 9.1 and summarized in table 5.11. The first batch of Phela capsule powders 
stored at room temperature were assessed for organoleptic features and were found to 
remain unchanged in size, shape, colour (light brown) and odour. On average, the five 
compounds of Phela (A to E) had lost 9.68 %, 9.07 %, 8.97 %, 9.25 % and 8.39 % of 
their original levels after 24 weeks of storage, respectively. Less than ten percent 
degradation of compounds A to E occurred, suggesting an average shelf-life of more 
than two years for the Phela capsules under these ambient test conditions. Although 
this result should be confirmed by study over a full 2-years period, the current 
information can already be used for future reference when Phela capsules are made.  
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Table 5.11: Average values of the compounds peak heights obtained in the stability study after 24 
weeks of storage under ambient condition. (N=3) 
 
 
Time 
(weeks) 
Peak Heights (ave ± SD, n =3) (mAUFs) 
Comp. A Comp. B  Comp. C Comp. D Comp. E 
0 4.1±0.1 5.4±0.2 5.8±0.2 6.5±0.4 5.6±0.5 
6 3.99±0.1 5.3±0.5 5.7±0.1 6.4±0.1 5.4±0.3 
14 3.98±0.2 5.1±0.2 5.4±0.1 6.2±0.3 5.2±0.2 
24 3.97±0.5 4.9±0.3 5.2±0.2 6.01±0.3 4.7±0.2 
 
The second batch of Phela capsules was stored in a plastic container under high 
temperature (40 ± 2 
0
C) and relative humidity (75 ± 5% RH) conditions for six 
months and samples taken every two weeks and analysed by HPLC. Although the 
capsules, after six months of storage, appeared sticky the organoleptic features of its 
contents appeared unchanged. The HPLC chromatograms were analysed and peaks 
exhibiting a typical flavonoids spectrum were identified, their retention times 
recorded and peak heights compared.  
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Figure 5. 4: A typical spectra of Phela material showing the peak heights and retention times 
of flavonoids after storage for 24 weeks.  
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Figure 5.4 is an example of a typical chromatogram obtained for the Phela mixture 
and an overlay of 5 peaks (i.e. A to E) representing single compounds with typical 
flavonoid spectrum is shown in figure 5.5. The peaks representing compounds A to E 
had retention times of 6.84±0.4, 8.008±0.3, 8.84±0.5, 9.09±0.3 and 10.188±0.1 
minutes, respectively. After 24 weeks storage, compounds A to E lost about 50 %, 
57.41 %, 63.79 %, 70.77 % and 82.14 % of their contents, respectively (see figure 5.6 
and Appendix 8.1).  After six months of storage, the selected compounds A to E 
degraded by more than 50 %. The same study of (Shah, et al, 2005) revealed that the 
formulations of A, B, and C also exhibited more than 50 % degradation of hypericin 
compared to its theoretical value and more than 30 % degradation of pseudohypericin.   
The change in the heights of peaks (or compounds) A to E over the 24 weeks of 
storage period are shown in figure 5.6.  
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Figure 5. 5: Overlay of HPLC fingerprints of Phela powder after different periods of storage 
at 40 C and 75% relative humidity. 4 fingerprints of capsules taken at 2 week 
interval are depicted.  
 
 
Shelf life (t90) is defined as the time required for a drug to decompose to 90 % of its 
initial concentration at a specific temperature, that is, when 10 % decomposition has 
occurred (Álvarez-Lueje. 2005).  On average, the five compounds had lost 22 % and 
70 % of their original levels after 12 and 24 weeks of storage, respectively, at the 
elevated temperature and humidity conditions. Ten percent degradation of compounds 
A to E occurred after 5.3, 6.3, 5.6, 4.1 and 5.5 weeks, respectively, suggesting an 
average shelf-life (i.e. t90) of 6.1±0.8 weeks for the Phela capsules under these 
accelerated test conditions. Although the active constituents of Phela are not known, 
the possibility is strong that the active constituents might show similar instability 
trends. 
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Figure 5. 6: Stability profile of Phela capsules over 24 weeks of storage at 40°C and 75% RH 
conditions measuring a change in HPLC peak heights for 5 compounds (A to E) 
after 2 weeks. 
 
The overall results of the stability study thus suggest that the contents of the capsules 
of Phela were stable under room temperature condition but not under high humidity 
and temperatures and that under such conditions the capsules would have no practical 
shelf life. It can also be concluded that the flavonoids, by being affected by the high 
temperature and humidity conditions could be used for the assessment of stability. 
Clearly the Phela capsules must not be stored under elevated temperature and 
humidity conditions, and the customary accelerated stability testing methods used for 
pharmaceuticals cannot be applied for this medicinal plant product. When kept under 
normal ambient conditions the capsules were however reasonably stable and should 
thus be viable for clinical trials and stored under ambient conditions. 
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5.3.4. Conclusion on Phela capsule. 
 
 
Overall, Phela capsules had an acceptable average weight of 0.42 ±0.01 g, which did 
not deviate from the set specification as required by the BP (2000). This means that 
Phela powders passed a uniformity of weight test. Although Phela capsules had not 
released 60 % of its contents at 60 minutes, the average amount of the material 
released for the six capsules of Phela were 50.5 ± 6.76 %. The manufactured capsules 
maintained their general appearance and physical properties under the humid 
conditions for six months of storage. The stability results obtained collectively 
indicated that the manufactured capsules essentially had no practical shelf life under 
accelerated condition but did have a practical shelf-life of more than two years stored 
under ambient condition. 
 
5.4 Certificate of Analysis (CoA) 
 
 
A Certificate of Analysis is a report usually sent to the customer at the time of 
shipping the finished goods. It contains information related to quality i.e. the quality 
characteristic, its specification or limit and the results obtained. Based on the results 
obtained in this study the CoA shown in table 5.12 can be drawn for the present Phela 
capsules. The detailed information on test/methods/procedure is indicated in the 
previous sections in this paper. 
 
 Although the results for particle size and shape and the degree of sphericity did not 
meet the required specifications, it did not complicate much in capsule filling of 
capsules since the capsules weights were well within the required specifications. The 
dissolution profile of Phela capsules did not meet the required specification (i.e. by 
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releasing 60 % of the contents in 60 minutes, the next batch of Phela capsules should 
meet the dissolution require.  Apart from the test/procedure indicated for Phela in 
table 5.12, there are other additional tests that can be explored (e.g. determination of 
tannins, assay chemicals, impurities, quantification of peaks etc) for material that 
could be presence/absence and also are important determinants to the quality of herbal 
material. As soon as above mentioned problems are realised then should not be a 
problem when submitting the certificate of analysis for clinical studies. 
 
Probably the most important aspect of clinical studies is CoA. ICH requires before the 
start of any clinical trial that the product must have a CoA that must have met 
specifications of analysis that ensure its quality, purity, and identity as required by the 
pharmacopoeias and drug regulations established for herbal drugs (ICH).   
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Table 5. 12: Certificate of analysis for Phela capsules 
 
Product: Phela     Dosage form: Capsule 
Batch no: P240574     Capsule size: 0 
 
 
 
Characteristic Test/Method/Procedure Specifications Results Conclusion 
 
Formulation: See section 4.2.2. for 
method 
A capsule containing 
mixture of 4 plants 
powders i.e. plant RM, 
CG, PT and S. *for 
property reason exact 
plant names and amount 
not given.  
Plant PT 
Plant CG 
Plant PT 
Plant S 
Complies 
Complies 
Complies 
Complies 
Identity: 
 Capsule 
Organoleptic  
Features (i.e. colour, 
odour, shape and size) by. 
visual, olfactory & tactile 
senses 
Consistency of  odour, 
taste & colour 
Yellow and brown 
capsule half’s,  
Biconvex, Oval shape. 
Size 0  
 
Conforms 
Identity:  
Phela material 
Macroscopic features (size 
and shape) 
Uniform in shape and size: 
Coarse powder: Not less 
than 95% by weight 
passes through a number 
1400 sieve and not more 
than 40% by weight 
passes through a number 
355 sieve. 
Non-uniform and not 
gradable 
 
Did not comply 
Identity:  
Phela material 
See section 4.2.3.2. for 
method 
Sphericity (θ):  <  2 3.17 ± 1.78 Did not comply 
See section 4.2.3.5. for 
method 
Ash values: 
 Range (5 – 6)% 
 
5.80±0.1% 
 
comply 
See section 4.2.3.3. for 
method 
Carr’s compressibility 
index: Range (5-10) 
3.98 ± 0.97 
 
comply 
See section 4.2.3.4. for 
method 
Angle of repose:  
Range (38-45)º 
37.92±1.280 
 
comply 
 See section 4.2.3.6. for 
method 
Moisture content level:  
≤ 10% 
9.77±0.08% 
 
comply 
See section 4.2.3.7. for 
method 
Water-soluble extractable 
fraction:  
Range (45 – 60)% 
47.43±3.80% comply 
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(table 5.12 continues) 
 
 
Levels of Microbial 
Contaminants 
 
Microbial test as per 
BP1993 
Absence of E. Coli (i.e.0 
CFU/G) 
Absence of Salmonella 
(i.e. 0 CFU/G) 
Absence of 
Staphylococcus (i.e. 0 
CFU/G) 
Yeast and Moulds  <  
100 CFU/G 
 
No growth 
 
No growth 
 
No growth 
 
No growth 
 
 
Conforms 
 
Conforms 
 
Conforms 
 
Conforms 
Levels of Pesticides  
 
 
Chemical test as per BP, 
EMEA, WHO 2007 
Absence of 
Organophosphate N/A 
Organonitrogen     N/A 
Organochloride     N/A 
N-Methyl Carbamate N/A 
(N/A = no official  
specification available) 
 
 
 
No residue detected 
No residue detected 
No residue detected 
No residue detected 
 
Conforms 
Conforms 
Conforms 
Conforms 
 
 Levels of Heavy metals : 
 
Chemical test as per 
BP1993, EMEA 2000, WHO 
2007 
Limits  
Arsenic  3 mg/kg 
Lead   10 mc/kg 
Mercury 3 mg/kg 
Cadmium N/A 
 
As   = 1.1 mg/kg 
Pb   = 6.4 mg/kg 
Hg   = 1.0 mg/kg 
Cd    = 0.5 mg/kg 
 
Complies 
Complies 
Complies 
Complies 
Uniformity of mass of 
dosage units 
As per BP 20006 ± 7.5 %  (Test Eur. Ph 5th 
Ed) 
 
 Complies 
Average mass As per BP 2000
6 235.1±7.5% 222.4 mg conforms 
Dissolution  As per BP 2000
5 Not less than 60%  of 
Phela capsules dissolved 
in 60 minutes in artificial 
gastric juices without 
enzymes 
50.5±6.76 Did not 
conform 
 
 
 
Stability as per  EMEA 
2007, WHO 
1996 
≥ 2 years stored under 
ambient conditions. 
≥ 2 years Conforms 
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Chapter 6 
 
Conclusions and Recommendations 
 
 
The aims and objectives of this study were to establish (from literature) a series of 
criteria and specifications that are appropriate to establish the pharmaceutical quality 
of plant-containing capsules such as Phela, assess the pharmaceutical quality of the 
finished Phela capsules, assess the pharmaceutical quality of the “formulated” Phela 
raw material and to provide a certificate of analysis for the finished capsules.  
 
The following hypotheses were postulated for the study, viz. that: 
 
Firstly, the capsule dosage form of Phela plant material would meet most of the general 
pharmacopoeial quality specifications, 
 
Secondly, the water extractable plant material contents of Phela capsules would be 
rapidly dissolving and meet the BP specification of 75 % of the extractable plant 
material dissolving in the acidic solution at pH 1.2 within 45 minutes, and  
 
Thirdly, that the Phela plant materials contain flavonoid-like compounds that will be 
susceptible to degradation and may be suitable as marker compounds to monitor the 
stability of the Phela capsules during storage. 
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From the results obtained the following conclusions could be drawn: 
 
1. There is a fairly good agreement, between various regulatory agencies, on the 
characteristics that could be used to assess the quality of herbal products as 
well as the methods and quality indication specifications (or tolerance limits) 
to use. Consequently it was concluded that the quality of the Phela capsules 
could be assessed by looking at the characteristics and specifications 
suggested by the World Health Organisation and in the British Pharmacopoeia 
and United States Pharmacopoeia. This entails an assessment of the physical 
attributes, chemical identity and quantity of plant active(s), microbial and 
other contaminant levels, content and mass uniformity, dissolution profile and 
stability profile of the Phela capsules and/or its contents which would provide 
a good idea of the quality of the Phela capsules (and its suitability for use in 
clinical trial).  
 
2. As far as pharmaceutical quality of the finished Phela capsules are concerned, 
the manufactured capsules conformed to the uniformity of weight specification 
as set by the BP. The capsules looked elegant and generally had a good 
physical appearance even after storage under humid conditions, but, under 
these conditions, unfortunately had no practical shelf life. 
  
The Phela capsules did not dissolved fully as expected in the dissolution media 
and only released about 50.5 ± 6.76 % of its contents in 45 minutes. As such, 
the Phela capsules therefore did not meet BP specifications of a fast releasing 
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capsule i.e. 75 % of the extractable plant material dissolving in the acidic 
solution at pH 1.2 within 45 minutes. .Phela capsules were concluded to have 
slow drug delivery potential. 
 
3.  The formulated Phela raw material generally was of good pharmaceutical 
quality, particularly in terms of flowability, moisture content levels and the 
heavy metal, pesticides and microbial levels which were all within the 
generally accepted specifications. There was an uneven distribution in particle 
size, but this did not appear to affect the uniformity of weight in the final 
dosage form and although the powders had a bitter taste, the formulation of 
powders into the capsules helped to mask the taste. The raw material thus 
conformed to most of the specifications but uneven particle size might be a 
problem (especially in large scale manufacture and/or irregular dissolution 
and/or in vivo bioavailability of the active constituents). 
 
4. The Phela capsules contained five selected flavonoid-like compounds (named 
compound A to E) that were useful as chemical markers to assess the stability 
profile of the manufactured Phela capsules. These marker compounds can be 
assayed by HPLC method but the latter was not fully validated in the present 
study.  
 
5. Finally, a certificate of analysis for the finished capsules was produced which 
generally suggested that the Phela capsules conforming to the CoA should be 
of consistent pharmaceutical quality and thus suitable for use in a clinical trial.  
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In addition to the above conclusions the following recommendations can be made 
based on the findings of this study 
 
Firstly, since the effect that the wide particle size distribution might have on the 
release and in vivo bioavailability of the actives from the Phela capsules attention may 
have to be given to reducing the wide particle size distribution of the Phela powders.  
This should be achievable by better milling and sieving during the production of the 
dry individual powders.  
 
Secondly, it might also be worthwhile to consider the use of extracts of the Phela 
plant powders obtained by using organic solvents (aqueous-alcoholic) in the Phela 
capsules. This may lead to substantially better dissolution rate that would be similar to 
that of obtained with the traditionally used decoction dosage form and possibly also 
improved in vivo bioavailability of the actives of the Phela plant materials.  
 
Thirdly, a one or more of the flavonoid peaks observed in the Phela material should 
be better identified (by LC-MS), a validated HPLC method established to quantitate it 
and the latter used to properly establish the stability of Phela and for use instability 
studies of pharmaceutical preparations containing Phela subjected to deterioration by 
hydrolysis, oxidation and chemical decarboxylation.  
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APPENDICES 
Appendix 1 
 
 
Particle size data for the four Phela plant and mixture powders (see section 
4.2.3.2 for method). 
 
 
Appendix 1.1 Particle size distribution of plant RM  
 
Serial no Sieve size 
(micron) 
Weight of 
plant powder 
retained (g) 
Plant powder 
retained on sieve 
(%)* 
1 500 0.879 8.79 
2 355 0.87 8.7 
3 180 1.593 15.93 
4 125 0.88 8.8 
5 90 2.741 27.41 
6 0 2.586 25.86 
total  9.549 95.49 
* Total amount of powder recovered as a percentage of the 10.02 g of sample introduced. 
 
 
1.2 Particle size distribution of plant CG 
 
 
Serial no Sieve size 
(micron) 
Weight of 
plant powder 
retained (g) 
Plant powder 
retained on sieve 
(%) 
1 500 0.67 6.7 
2 355 0.867 8.67 
3 180 2.606 26.06 
4 125 1.42 14.2 
5 90 2.14 21.4 
6 0 1.584 15.84 
total  9.287 92.87 
* Total amount of powder recovered as a percentage of the 10.04 g of sample introduced. 
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1.3 Particle size distribution of plant PT 
 
 
Serial no Sieve size 
(micron) 
Weight of 
plant powder 
retained (g) 
Plant powder 
retained on sieve 
(%) 
1 500 0.601 6.01 
2 355 0.768 7.68 
3 180 1.833 18.33 
4 125 1.722 17.22 
5 90 3.931 39.31 
6 0 0.594 5.94 
total  9.449 94.49 
* Total amount of powder recovered as a percentage of the 10.06 g of sample introduced. 
 
1.4 Particle size distribution of plant S 
 
Serial no Sieve size 
(micron) 
Weight of 
plant powder 
retained (g) 
Plant powder 
retained on sieve 
(%) 
1 500 0.633 6.33 
2 355 1.563 15.63 
3 180 3.339 33.39 
4 125 1.105 11.05 
5 90 1.709 17.09 
6 0 1.184 11.84 
total  9.533 95.33 
* Total amount of powder recovered as a percentage of the 10.07 g of sample introduced. 
 
1.5 Particle size distribution of plant Phela 
 
Serial no Sieve size 
(micron) 
Weight of 
plant powder 
retained (g) 
Plant powder 
retained on sieve 
(%) 
1 500 0.762 7.62 
2 355 0.961 9.61 
3 180 2.444 24.44 
4 125 0.827 8.27 
5 90 2.266 22.66 
6 0 2.096 20.96 
total  9.356 93.56 
* Total amount of powder recovered as a percentage of the 10.05 g of sample introduced
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Appendix 2 
 
Particle shape data for the four Phela individual plant and mixture powders (see 
section 4.2.3.2 for method) 
 
Append 2.1   Numbers of particles of Plant RM with different length (A) and 
breadth (B).  The N = length / breadth for each particle was calculated 
and averaged to give the degree of sphericity (θ) = 3.38 ± 2.32 (n = 100 
particles) 
 
 
 
Distribution of particle size (breadth) 
0 
10 
20 
30 
40 
50 
60 
70 
50 to 100 100 to 200 200 to 300 300 to 400 
Particle breadth (um) 
Series1 
Distribution of particle size (length) 
0 
5 
10 
15 
20 
25 
30 
35 
200 to 
300  
300 to 
400 
400 to 
500 
500 to 
600 
600 to 
700 
700 to 
800 
800 to 
900 
900 to 
1000 
Particle length (um) 
Series1 
 99 
Append 2.2   Numbers of particles of Plant CG with different length (A) and breadth 
(B).  The N = length / breadth for each particle was calculated and 
averaged to give the degree of sphericity (θ) = 3.60 ± 1.44 (n = 100 
particles) 
 
 
 
 
 
         
 
Distribution of particle ( length) 
0 
5 
10 
15 
20 
25 
250 to 
300  
300 to 
400 
400 to 
500 
500 to 
600 
600 to 
700 
700 to 
800 
800 to 
900 
900 to 
1000 
Particle length (um) 
Series1 
Distribution of particle size (breadth) 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 to 100 100 to 200 200 to 300 300 to 400 
Particle breadth (um) 
Series1 
 100 
 
Append 2.3  Numbers of particles of Plant PT with different length (A) and breadth 
(B).  The N = length / breadth for each particle was calculated and 
averaged to give the degree of sphericity (θ) = 1.19 ± 0.63 (n = 100 
particles) 
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Append 2.4   Numbers of particles of Plant S with different length (A) and breadth 
(B).  The N = length / breadth for each particle was calculated and 
averaged to give the degree of sphericity (θ) = 3.72 ± 1.88 (n = 100 
particles) 
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Append 2.5   Numbers of particles of Phela mixture with different length (A) and 
breadth (B).  The N = length / breadth for each particle was calculated 
and averaged to give the degree of sphericity (θ) = 3.17 ± 1.78 (n = 100 
particles) 
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Appendix 3 
 
Microbial contaminant level results  for  the Phela plant 
powders.  
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Appendix 4 
 
Certificate of analysis of Phela : heavy metal levels  
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Appendix 5 
 
Certificate of Analysis of Phela:  pesticide residue levels 
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Appendix 6 
 
 
HPLC fingerprints of the four plant materials and Phela 
mixture 
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Figure A6. 1: HPLC fingerprint for extract of plant S.  UV detection wavelength set at 300 nm 
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 Figure A6. 2: HPLC fingerprint for extract of CG. UV detection wavelength set at 300 nm 
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Figure A6.3:  HPLC fingerprint for extract of RM. UV detection wavelength set at 300 nm 
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Figure A6. 4: HPLC fingerprint for extract of PT. UV detection wavelength set at 300 nm  
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Figure A6. 5: HPLC fingerprint for Phela extract. UV detection wavelength set at 300 nm  
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Appendix 7 
  Weight uniformity of for Phela capsule 
 
Table A7: Weight uniformity test results for Phela capsules 
 
 
 
 
 
*Deviation in weight (g) = [Weight of content (g) - Average weight of content (g)] 
100 % / Average of contents  
 
 Weight of 
whole 
capsule  
(mg) 
Weight of 
emptied 
capsule- shell 
(mg) 
Weight of 
capsule-
contents  
(mg) 
*Deviation 
In weight from 
average 
(%)  
1 0.401 0.0932 0.3078 4.41 
2 0.4236 0.0936 0.3300 2.48 
3 0.41 0.0947 0.3153 2.08 
4 0.421 0.0956 0.3254 1.06 
5 0.428 0.0959 0.3321 3.14 
6 0.431 0.0933 0.3377 4.88 
7 0.402 0.0977 0.3043 5.5 
8 0.417 0.0967 0.3203 5.2 
9 0.4295 0.0954 0.3341 3.76 
10 0.411 0.0943 0.3167 1.65 
11 0.4098 0.0941 0.3157 1.96 
12 0.423 0.0952 0.3278 1.61 
13 0.4302 0.0973 0.3329 3.39 
14 0.409 0.0911 0.3179 1.27 
15 0.412 0.0959 0.3161 1.83 
16 0.4275 0.0968 0.3307 2.70 
17 0.421 0.0947 0.3263 1.34 
18 0.4001 0.0924 0.3077 4.44 
19 0.4101 0.0955 0.3146 2.30 
20 0.4211 0.0958 0.3253 1.02 
Mean 0.42 0.09 0.32 2.80 
SD ±0.01 ±0.002 ±0.01 ±1.45 
relative standard 
deviation 
1.76 3.00  
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Appendix 8 
Dissolution profile of Phela Capsules 
Table A8: Percentage drug release of six Phela capsules over time in a 
dissolution medium at pH 1.2 and 37 
0
C. 
 
 
 
 
 
Time 
(min) 
 
Capsule 
1(%) 
Capsule 2 
(%) 
Capsule 3 
(%) 
Capsule 4 
(%) 
Capsule 5 
(%) 
Capsule 6 
(%) 
Ave SD 
0 3.92 4.64 4.4 4.98 4.75 4.93 4.60 ±0.39 
15 28.43 36.17 37.13 43.61 27.44 30.93 33.95 ±6.17 
30 36.88 46.84 49.12 47.77 54.51 41.28 46.07 ±6.19 
45 40.61 51.19 56.38 51.19 58.59 45.02 50.5 ±6.76 
60 76.08 84.48 84.01 79.78 82.11 69.49 79.32 ±5.72 
75 86.68 95.18 93.02 97.85 90.47 81.74 90.82 ±5.88 
90 94.84 99.98 96.49 94.79 93.87 95.79 95.96 ±2.17 
120 100 100 100 100 100 100   
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Appendix 9 
 
Chromatograms and “flavonoid or selected” peak heights 
obtained in the stability study 
 
 
 
Figure A9.1: HPLC chromatogram of capsule stored at 40 
0
C & 70 % RH and 
analysed every after 2 weeks. Heights of peaks at Rt = (6.845, 8.014, 8.950, 9.104 
and 10.198) min representing flavonoids are monitored. 
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Table A9.1: Average values of the compounds peak heights obtained in the 
stability study after 24 weeks. (N=3) 
 
 
Time Comp. A Comp. B  Comp. C Comp. D Comp. E Average 
0 4±0.1 5.4±0.2 5.8±0.2 6.5±0.4 5.6±0.5 5.46 
2 3.96±0.1 5.3±0.2 5.8±0.2 6.5±0.2 5.6±0.4 5.432 
4 3.8±0.1 5.0±0.1 4.9±0.1 6.03±0.2 5.1±0.1 4.966 
6 3.79±0.1 5.0±0.1 4.4±0.2 5.7±0.2 5.3±0.2 4.838 
8 3.6±0.1 5.3±0.1 4.7±0.1 5.9±0.1 4.9±0.1 4.88 
10 3.5±0.1 4.9±0.1 3.7±0.2 5.4±0.1 4.7±0.1 4.44 
12 3.5±0.1 4.6±0.3 4.4±0.1 4.7±0.2 4±0.1 4.24 
14 3.3±0.1 4.5±0.2 4.2±0.1 4.6±0.1 3.5±0.2 4.02 
16 3.4±0.1 4±0.1 3.7±0.2 4.2±0.3 2.6±0.2 3.58 
18 3.4±0.1 3.7±0.1 3.6±0.1 3.9±0.1 2.5±0.1 3.42 
20 3.2±0.2 3.6±0.2 3.5±0.1 3.2±0.3 2.2±0.2 3.14 
22 2.7±0.6 3.1±0.1 2.4±0.8 2.8±0.1 1.9±0.3 2.58 
24 2±0.1 2.3±0.3 2.1±0.2 1.9±0.3 1±0.2 1.6 
 
 
 
 
 
 
  
